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The medical profession should play a central role in
evaluating evidence related to drugs, devices, and pro-
cedures for detection, management, and prevention of
disease. When properly applied, expert analysis of avail-
able data on the beneﬁts and risks of these therapies and
procedures can improve the quality of care, optimize pa-
tient outcomes, and favorably affect costs by focusing
resources on the most effective strategies. An organized
and directed approach to a thorough review of evidence
has resulted in the production of clinical practice guide-
lines that assist clinicians in selecting the best manage-
ment strategy for an individual patient. Moreover, clinical
practice guidelines can provide a foundation for other
applications, such as performance measures, appropriate
use criteria, and both quality improvement and clinical
decision support tools.
The American College of Cardiology (ACC) and the
American Heart Association (AHA) have jointly engaged
in the production of guidelines in the area of cardiovascular
disease since 1980. The ACC/AHA Task Force on
Practice Guidelines (Task Force) directs this effort by
developing, updating, and revising practice guidelines for
cardiovascular diseases and procedures.
Experts in the subject under consideration are selected
from both ACC and AHA to examine subject-speciﬁc
data and write guidelines. Writing committees are spe-
ciﬁcally charged with performing a literature review;
weighing the strength of evidence for or against particular
tests, treatments, or procedures; and including estimates of
expected health outcomes where such data exist. Patient-
speciﬁc modiﬁers, comorbidities, and issues of patient
preference that may inﬂuence the choice of tests or ther-
apies are considered, as well as frequency of follow-up andcost effectiveness. When available, information from
studies on cost is considered; however, a review of data on
efﬁcacy and outcomes constitutes the primary basis for
preparing recommendations in this guideline.
In analyzing the data and developing recommendations
and supporting text, the writing committee uses evidence-
based methodologies developed by the Task Force (1). The
Class of Recommendation (COR) is an estimate of the size
of the treatment effect, with consideration given to risks
versus beneﬁts, as well as evidence and/or agreement that a
given treatment or procedure is or is not useful/effective or
in some situations may cause harm. The Level of Evidence
(LOE) is an estimate of the certainty or precision of the
treatment effect. The writing committee reviews and ranks
evidence supporting each recommendation, with the
weight of evidence ranked as LOE A, B, or C, according
to speciﬁc deﬁnitions. The schema for the COR and LOE
is summarized in Table 1, which also provides suggested
phrases for writing recommendations within each COR.
Studies are identiﬁed as observational, retrospective,
prospective, or randomized, as appropriate. For certain
conditions for which inadequate data are available, rec-
ommendations are based on expert consensus and clinical
experience and are ranked as LOE C. When recommen-
dations at LOE C are supported by historical clinical data,
appropriate references (including clinical reviews) are cited
if available. For issues with sparse available data, a survey of
current practice among the clinician members of the
writing committee is the basis for LOE C recommenda-
tions and no references are cited.
A new addition to this methodology is separation of the
Class III recommendations to delineate whether the
recommendation is determined to be of “no beneﬁt” or is
associated with “harm” to the patient. In addition, in view
of the increasing number of comparative effectiveness
studies, comparator verbs and suggested phrases for writing
recommendations for the comparative effectiveness of one
treatment or strategy versus another are included for COR
I and IIa, LOE A or B only.
In view of the advances in medical therapy across the
spectrum of cardiovascular diseases, the Task Force has
designated the term guideline-directed medical therapy
(GDMT) to represent optimal medical therapy as
deﬁned by ACC/AHA guideline (primarily Class I)-
recommended therapies. This new term, GDMT, is
used herein and throughout subsequent guidelines.
Because the ACC/AHA practice guidelines address
patient populations (and clinicians) residing in North
America, drugs that are not currently available in North
America are discussed in the text without a speciﬁc COR.
For studies performed in large numbers of subjects outside
North America, each writing committee reviews the po-
tential impact of different practice patterns and patient
populations on the treatment effect and relevance to the
ACC/AHA target population to determine whether the
ﬁndings should inform a speciﬁc recommendation.
Table 1. Applying Classiﬁcation of Recommendations and Level of Evidence
A recommendation with Level of Evidence B or C does not imply that the recommendation is weak. Many important clinical questions addressed in the guidelines do not lend themselves to clinical trials.
Although randomized trials are unavailable, there may be a very clear clinical consensus that a particular test or therapy is useful or effective.
*Data available from clinical trials or registries about the usefulness/efﬁcacy in different subpopulations, such as sex, age, history of diabetes mellitus, history of prior myocardial infarction, history of
heart failure, and prior aspirin use.
yFor comparative-effectiveness recommendations (Class I and IIa; Level of Evidence A and B only), studies that support the use of comparator verbs should involve direct comparisons of the treatments
or strategies being evaluated.
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2441The ACC/AHA practice guidelines are intended to
assist clinicians in clinical decision making by describing a
range of generally acceptable approaches to the diagnosis,
management, and prevention of speciﬁc diseases or con-
ditions. The guidelines attempt to deﬁne practices that
meet the needs of most patients in most circumstances.
The ultimate judgment about care of a particular patient
must be made by the clinician and patient in light of all the
circumstances presented by that patient. As a result, situ-
ations may arise in which deviations from these guidelines
may be appropriate. Clinical decision making should
involve consideration of the quality and availability of
expertise in the area where care is provided. When these
guidelines are used as the basis for regulatory or payerdecisions, the goal should be improvement in quality of
care. The Task Force recognizes that situations arise in
which additional data are needed to inform patient care
more effectively; these areas are identiﬁed within each
respective guideline when appropriate.
Prescribed courses of treatment in accordance with these
recommendations are effective only if followed. Because
lack of patient understanding and adherence may adversely
affect outcomes, clinicians should make every effort to
engage the patient’s active participation in prescribed
medical regimens and lifestyles. In addition, patients
should be informed of the risks, beneﬁts, and alternatives
to a particular treatment and should be involved in shared
decision making whenever feasible, particularly for COR
Nishimura et al. JACC Vol. 63, No. 22, 2014
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2442IIa and IIb, for which the beneﬁt-to-risk ratio may be
lower.
The Task Force makes every effort to avoid actual, po-
tential, or perceived conﬂicts of interest that may arise as a
result of relationships with industry and other entities
(RWI) among the members of the writing committee. All
writing committee members and peer reviewers of the
guideline are required to disclose all current healthcare-
related relationships, including those existing 12 months
before initiation of the writing effort.
In December 2009, the ACC and AHA implemented a
new RWI policy that requires the writing committee chair
plus a minimum of 50% of the writing committee to
have no relevant RWI (Appendix 1 includes the ACC/
AHA deﬁnition of relevance). The Task Force and all
writing committee members review their respective RWI
disclosures during each conference call and/or meeting of
the writing committee, and members provide updates to
their RWI as changes occur. All guideline recommenda-
tions require a conﬁdential vote by the writing committee
and require approval by a consensus of the voting mem-
bers. Authors’ and peer reviewers’ RWI pertinent to this
guideline are disclosed in Appendixes 1 and 2. Members
may not draft or vote on any recommendations
pertaining to their RWI. Members who recused them-
selves from voting are indicated in the list of writing
committee members with speciﬁc section recusals noted
in Appendix 1. In addition, to ensure complete trans-
parency, writing committee members’ comprehensive
disclosure informationdincluding RWI not pertinent to
this documentdis available as an online supplement.
Comprehensive disclosure information for the Task
Force is also available online at http://www.cardiosource.
org/en/ACC/About-ACC/Who-We-Are/Leadership/
Guidelines-and-Documents-Task-Forces.aspx. The ACC
and AHA exclusively sponsor the work of the writing
committee without commercial support. Writing com-
mittee members volunteered their time for this activity.
Guidelines are ofﬁcial policy of both the ACC and AHA.
In an effort to maintain relevance at the point of care
for clinicians, the Task Force continues to oversee an
ongoing process improvement initiative. As a result, several
changes to these guidelines will be apparent, including
limited narrative text, a focus on summary and evidence
tables (with references linked to abstracts in PubMed), and
more liberal use of summary recommendation tables (with
references that support LOE) to serve as a quick reference.
In April 2011, the Institute of Medicine released 2
reports: Finding What Works in Health Care: Standards
for Systematic Reviews and Clinical Practice Guidelines
We Can Trust (2,3). It is noteworthy that the Institute
of Medicine cited ACC/AHA practice guidelines as be-
ing compliant with many of the proposed standards.
A thorough review of these reports and of our current
methodology is under way, with further enhancements
anticipated.The recommendations in this guideline are considered
current until they are superseded by a focused update,
the full-text guideline is revised, or until a published
addendum declares it out of date and no longer ofﬁcial
ACC/AHA policy. The reader is encouraged to consult
the full-text guideline (4) for additional guidance and
details about valvular heart disease (VHD), since the ex-
ecutive summary contains only the recommendations.
Jeffrey L. Anderson, MD, FACC, FAHA
Chair, ACC/AHA Task Force on Practice Guidelines
1. Introduction
1.1. Methodology and Evidence Review
The recommendations listed in this document are,
whenever possible, evidence based. An extensive review
was conducted on literature published through November
2012, and other selected references through October
2013 were reviewed by the guideline writing committee.
The relevant data are included in evidence tables in the
Data Supplement. Searches were extended to studies,
reviews, and other evidence conducted on human subjects
and that were published in English from PubMed,
EMBASE, Cochrane, Agency for Healthcare Research
and Quality Reports, and other selected databases rele-
vant to this guideline. Key search words included but were
not limited to the following: valvular heart disease, aortic
stenosis, aortic regurgitation, bicuspid aortic valve, mitral
stenosis, mitral regurgitation, tricuspid stenosis, tricuspid
regurgitation, pulmonic stenosis, pulmonic regurgitation,
prosthetic valves, anticoagulation therapy, infective endo-
carditis, cardiac surgery, and transcatheter aortic valve
replacement. Additionally, the committee reviewed docu-
ments related to the subject matter previously published
by the ACC and AHA. The references selected and
published in this document are representative and not
all-inclusive.
1.2. Organization of the Writing Committee
The committee was composed of clinicians, who included
cardiologists, interventionalists, surgeons, and anesthesi-
ologists. The committee included representatives from
the American Association for Thoracic Surgery, American
Society of Echocardiography (ASE), Society for Cardio-
vascular Angiography and Interventions, Society of Car-
diovascular Anesthesiologists, and Society of Thoracic
Surgeons (STS).
1.3. Document Review and Approval
This document was reviewed by 2 ofﬁcial reviewers each
nominated by both the ACC and the AHA, as well as 1
reviewer each from the American Association for Thoracic
Surgery, ASE, Society for Cardiovascular Angiography and
Interventions, Society of Cardiovascular Anesthesiologists,
and STS and 39 individual content reviewers (which
JACC Vol. 63, No. 22, 2014 Nishimura et al.
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2443included representatives from the following ACC com-
mittees and councils: Adult Congenital and Pediatric
Cardiology Section, Association of International Gover-
nors, Council on Clinical Practice, Cardiovascular Section
Leadership Council, Geriatric Cardiology Section Lead-
ership Council, Heart Failure and Transplant Council,
Interventional Council, Lifelong Learning Oversight
Committee, Prevention of Cardiovascular Disease Com-
mittee, and Surgeon Council). Reviewers’ RWI informa-
tion was distributed to the writing committee and is
published in this document (Appendix 2).
This document was approved for publication by the
governing bodies of the ACC and the AHA and endorsed
by the American Association for Thoracic Surgery, ASE,
Society for Cardiovascular Angiography and Interventions,
Society of Cardiovascular Anesthesiologists, and STS.1.4. Scope of the Guideline
The focus of this guideline is the diagnosis and manage-
ment of adult patients with valvular heart disease (VHD).
A full revision of the original 1998 VHD guideline was
made in 2006, and an update was made in 2008 (5). Some
recommendations from the earlier VHD guidelines have
been updated as warranted by new evidence or a better
understanding of earlier evidence, whereas others that
were inaccurate, irrelevant, or overlapping were deleted or
modiﬁed. Throughout, our goal was to provide the clini-
cian with concise, evidence-based, contemporary recom-
mendations and the supporting documentation to
encourage their use.
The full-text version of this guideline (4) was created in
a different format from prior VHD guidelines to facilitate
access to concise, relevant bytes of information at the
point of care when clinical knowledge is needed the most.
Thus, each COR is followed by a brief paragraph of sup-
porting text and references. Where applicable, sections
were divided into subsections of 1) diagnosis and follow-Table 2. Associated Guidelines and Statements
Title
Recommendations for Evaluation of the Severity of Native Valvular Regurgitation Wit
Doppler Echocardiography
Guidelines for the Management of Adults With Congenital Heart Disease
Echocardiographic Assessment of Valve Stenosis: EAE/ASE Recommendations for Cli
Recommendations for Evaluation of Prosthetic Valves With Echocardiography and Do
Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy
Guidelines on the Management of Cardiovascular Diseases During Pregnancy
Antithrombotic and Thrombolytic Therapy for Valvular Disease: Antithrombotic Therap
Guidelines on the Management of Valvular Heart Disease
Guideline for the Management of Heart Failure
Guideline for the Management of Patients With Atrial Fibrillation
ACC indicates American College of Cardiology; ACCF, American College of Cardiology Foundation; ACC
ASE, American Society of Echocardiography; EACTS, European Association for Cardio-Thoracic Surgery;
valvular heart disease.up, 2) medical therapy, and 3) intervention. The purpose
of these subsections was to categorize the COR according
to the clinical decision-making pathways that caregivers
use in the management of patients with VHD. New rec-
ommendations for assessment of the severity of valve le-
sions have been proposed, based on current natural history
studies of patients with VHD. The relevant data are
included in evidence tables in the Data Supplement of the
full-text guideline (4).
The present document applies to adult patients with
VHD. Management of patients with congenital heart
disease (CHD) and infants and children with valve disease
are not addressed here. The document recommends a
combination of lifestyle modiﬁcations and medications
that constitute GDMT. Both for GDMT and other rec-
ommended drug treatment regimens, the reader is advised
to conﬁrm dosages with product insert material and to
carefully evaluate for contraindications and drug–drug in-
teractions. Table 2 is a list of associated guidelines that may
be of interest to the reader. The table is intended for use as
a resource and obviates the need to repeat extant guideline
recommendations.
2. General Principles
2.1. Evaluation of the Patient With
Suspected VHD
Patients with VHD may present with a heart murmur,
symptoms, or incidental ﬁndings of valvular abnormalities
on chest imaging or noninvasive testing. Irrespective of the
presentation, all patients with known or suspected VHD
should undergo an initial meticulous history and physical
examination, as well as a chest x-ray and electrocardiogram.
A comprehensive transthoracic echocardiogram (TTE)
with 2-dimensional imaging and Doppler interrogation
should then be performed to correlate ﬁndings with
initial impressions based on the initial clinical evaluation.Organization
Publication
Year/Reference
h Two-Dimensional and ASE 2003 (6)
ACC/AHA 2008 (8)
nical Practice EAE/ASE 2009 (9)
ppler Ultrasound ASE 2009 (10)
ACCF/AHA 2011 (11)
ESC 2011 (12)
y and Prevention of Thrombosis ACCP 2012 (13)
ESC/EACTS 2012 (14)
ACCF/AHA 2013 (15)
AHA/ACC/HRS 2014 (16)
P, American College of Chest Physicians; AF, atrial ﬁbrillation; AHA, American Heart Association;
EAE, European Association of Echocardiography; ESC, European Society of Cardiology; and VHD,
Table 3. Stages of Progression of VHD
Stage Deﬁnition Description
A At risk Patients with risk factors for development of VHD
B Progressive Patients with progressive VHD (mild-to-moderate
severity and asymptomatic)
C Asymptomatic
severe
Asymptomatic patients who have the criteria for
severe VHD:
C1: Asymptomatic patients with severe VHD in whom
the left or right ventricle remains compensated
C2: Asymptomatic patients with severe VHD, with
decompensation of the left or right ventricle
D Symptomatic
severe
Patients who have developed symptoms as a result
of VHD
VHD indicates valvular heart disease.
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2444The TTE will also be able to provide additional infor-
mation, such as the effect of the valve lesion on
the cardiac chambers and great vessels, and to assess for
other concomitant valve lesions. Other ancillary testing
such as transesophageal echocardiography (TEE), com-
puted tomography (CT) or cardiac magnetic resonance
(CMR) imaging, stress testing, and diagnostic hemody-
namic cardiac catheterization may be required to deter-
mine the optimal treatment for a patient with VHD. An
evaluation of the possible surgical risk for each individual
patient should be performed if intervention is contem-
plated, as well as other contributing factors such as the
presence and extent of comorbidities and frailty. Follow-
up of these patients is important and should consist
of an annual history and physical examination in most
stable patients. An evaluation of the patient may be
necessary sooner than annually if there is a change in the
patient’s symptoms. In some valve lesions there may be
unpredictable adverse consequences on the left ventricle
in the absence of symptoms necessitating more frequent
follow-up. The frequency of repeat testing, such as
echocardiography, will be dependent on the severity of
the valve lesion and its effect on the left or right ventricle,
coupled with the known natural history of the valve
lesion.
2.2. Deﬁnitions of Severity of Valve Disease
Classiﬁcation of the severity of valve lesions should be
based on multiple criteria, including the initial ﬁndings
on the physical examination, which should then be corre-
lated with data from a comprehensive TTE. Intervention
should primarily be performed on patients with severe
VHD in addition to other criteria outlined in this
document.
This document provides a classiﬁcation of the progres-
sion of VHD with 4 stages (A to D) similar to that pro-
posed by the “2013 ACCF/AHA Guideline for the
Management of Heart Failure” (18). Indication for inter-
vention in patients with VHD is dependent on 1) the
presence or absence of symptoms; 2) the severity of VHD;
3) the response of the left and/or right ventricle to the
volume or pressure overload caused by VHD; 4) the effect
on the pulmonary or systemic circulation; and 5) a change
in heart rhythm. The stages take into consideration all of
these important factors (Table 3). The criteria for the stages
of each individual valve lesion are listed in Section 3.1,
Section 4.1, Section 6.1, Section 7.1, Section 8.1, Section
8.3, and Section 9.
The purpose of valvular intervention is to improve
symptoms and/or prolong survival, as well as to minimize
the risk of VHD-related complications such as asymp-
tomatic irreversible ventricular dysfunction, pulmonary
hypertension, stroke, and atrial ﬁbrillation (AF). Thus, the
criteria for “severe” VHD are based on studies describing
the natural history of patients with unoperated VHD, as
well as observational studies relating the onset of symptomsto measurements of severity. In patients with stenotic le-
sions, there is an additional category of “very severe” ste-
nosis based on studies of the natural history showing that
prognosis becomes poorer as the severity of stenosis
increases.
2.3. Diagnostic TestingdDiagnosis and
Follow-Up: Recommendations
See Table 4 for the frequency of echocardiograms in
asymptomatic patients with VHD and normal left ven-
tricular (LV) function.
CLASS I
1. TTE is recommended in the initial evaluation of patients with
known or suspected VHD to conﬁrm the diagnosis, establish
etiology, determine severity, assess hemodynamic conse-
quences, determine prognosis, and evaluate for timing of
intervention (19–34). (Level of Evidence: B)
2. TTE is recommended in patients with known VHD with any
change in symptoms or physical examination ﬁndings. (Level of
Evidence: C)
3. Periodic monitoring with TTE is recommended in asymptomatic
patients with known VHD at intervals depending on valve lesion,
severity, ventricular size, and ventricular function. (Level of
Evidence: C)
4. Cardiac catheterization for hemodynamic assessment is rec-
ommended in symptomatic patients when noninvasive tests are
inconclusive or when there is a discrepancy between the ﬁnd-
ings on noninvasive testing and physical examination regarding
severity of the valve lesion. (Level of Evidence: C)
CLASS IIa
1. Exercise testing is reasonable in selected patients with asymp-
tomatic severe VHD to 1) conﬁrm the absence of symptoms, or
2) assess the hemodynamic response to exercise, or 3) determine
prognosis (35–39). (Level of Evidence: B)2.4. Basic Principles of Medical Therapy:
Recommendations
CLASS I
1. Secondary prevention of rheumatic fever is indicated in patients
with rheumatic heart disease, speciﬁcally mitral stenosis (MS)
(40). (Level of Evidence: C)
Table 4. Frequency of Echocardiograms in Asymptomatic Patients With VHD and Normal Left Ventricular Function
Stage Valve Lesion
Stage Aortic Stenosis* Aortic Regurgitation Mitral Stenosis Mitral Regurgitation
Progressive
(stage B)
Every 3–5 y
(mild severity Vmax 2.0–2.9 m/s)
Every 3–5 y (mild severity)
Every 1–2 y (moderate severity)
Every 3–5 y
(MVA >1.5 cm2)
Every 3–5 y (mild severity)
Every 1–2 y (moderate severity)
Every 1–2 y
(moderate severity Vmax 3.0–3.9 m/s)
Severe
(stage C)
Every 6–12 mo
(Vmax 4 m/s)
Every 6–12 mo
Dilating LV: more frequently
Every 1–2 y
(MVA 1.0–1.5 cm2)
Once every year
(MVA <1.0 cm2)
Every 6–12 mo
Dilating LV: more frequently
Patients with mixed valve disease may require serial evaluations at intervals earlier than recommended for single valve lesions.
*With normal stroke volume.
LV indicates left ventricle; MVA, mitral valve area; VHD, valvular heart disease; and Vmax, maximum velocity.
Table 5. Risk Assessment Combining STS Risk Estimate, Frailty, Major Organ System Dysfunction,
and Procedure-Speciﬁc Impediments
Low Risk
(Must Meet ALL Criteria
in This Column)
Intermediate Risk
(Any 1 Criterion
in This Column)
High Risk
(Any 1 Criterion
in This Column)
Prohibitive Risk
(Any 1 Criterion
in This Column)
STS PROM* <4%
AND
4%–8%
OR
>8%
OR
Predicted risk with surgery of death
or major morbidity (all-cause)
>50% at 1 y
OR
Frailtyy None
AND
1 Index (mild)
OR
2 Indices (moderate to severe)
OR
Major organ system compromise
not to be improved postoperativelyz
None
AND
1 Organ system
OR
No more than 2 organ systems
OR
3 Organ systems
OR
Procedure-speciﬁc impedimentx None Possible procedure-speciﬁc
impediment
Possible procedure-speciﬁc
impediment
Severe procedure-speciﬁc
impediment
*Use of the STS PROM to predict risk in a given institution with reasonable reliability is appropriate only if institutional outcomes are within 1 standard deviation of STS average observed/expected ratio
for the procedure in question.
ySeven frailty indices: Katz Activities of Daily Living (independence in feeding, bathing, dressing, transferring, toileting, and urinary continence) and independence in ambulation (no walking aid or assist
required or 5-meter walk in <6 s). Other scoring systems can be applied to calculate no, mild-, or moderate-to-severe frailty.
zExamples of major organ system compromise: Cardiacdsevere LV systolic or diastolic dysfunction or RV dysfunction, ﬁxed pulmonary hypertension; CKD stage 3 or worse; pulmonary dysfunction with
FEV1 <50% or DLCO2 <50% of predicted; CNS dysfunction (dementia, Alzheimer’s disease, Parkinson’s disease, CVA with persistent physical limitation); GI dysfunctiondCrohn’s disease, ulcerative
colitis, nutritional impairment, or serum albumin <3.0; cancerdactive malignancy; and liverdany history of cirrhosis, variceal bleeding, or elevated INR in the absence of VKA therapy.
xExamples: tracheostomy present, heavily calciﬁed ascending aorta, chest malformation, arterial coronary graft adherent to posterior chest wall, or radiation damage.
CKD indicates chronic kidney disease; CNS, central nervous system; CVA, stroke; DLCO2, diffusion capacity for carbon dioxide; FEV1, forced expiratory volume in 1 s; GI, gastrointestinal; INR,
international normalized ratio; LV, left ventricular; PROM, predicted risk of mortality; RV, right ventricular; STS, Society of Thoracic Surgeons; and VKA, vitamin K antagonist.
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1. Prophylaxis against infective endocarditis (IE) is reasonable
for the following patients at highest risk for adverse outcomes
from IE before dental procedures that involve manipulation
of gingival tissue, manipulation of the periapical region of teeth, or
perforation of the oral mucosa (41–43) (Level of Evidence: B):
 Patients with prosthetic cardiac valves;
 Patients with previous IE;
 Cardiac transplant recipients with valve regurgitation due to
a structurally abnormal valve; or
 Patients with CHD with:
B Unrepaired cyanotic CHD, including palliative shunts and
conduits;
B Completely repaired congenital heart defect repaired with
prosthetic material or device, whether placed by surgery
or catheter intervention, during the ﬁrst 6 months after
the procedure; or
B Repaired CHD with residual defects at the site or adja-
cent to the site of a prosthetic patch or prosthetic device.CLASS III: No Beneﬁt
1. Prophylaxis against IE is not recommended in patients with
VHD who are at risk of IE for nondental procedures (e.g., TEE,
esophagogastroduodenoscopy, colonoscopy, or cystoscopy)
in the absence of active infection (44). (Level of Evidence: B)2.5. Evaluation of Surgical and
Interventional Risk
See Table 5 for risk assessment combining STS risk esti-
mate, frailty, major organ system dysfunction, and
procedure-speciﬁc impediments.
2.6. The Heart Valve Team and Heart Valve
Centers of Excellence: Recommendations
CLASS I
1. Patients with severe VHD should be evaluated by a multidisci-
plinary Heart Valve Team when intervention is considered.
(Level of Evidence: C)
CLASS IIa
1. Consultation with or referral to a Heart Valve Center of Excel-
lence is reasonable when discussing treatment options for 1)
asymptomatic patients with severe VHD, 2) patients who may
beneﬁt from valve repair versus valve replacement, or 3)
patients with multiple comorbidities for whom valve intervention
is considered. (Level of Evidence: C)
A competent, practicing cardiologist should have the
ability to diagnose and direct the treatment of most patients
with VHD. For instance, otherwise healthy patients with
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2446severe VHDwho become symptomatic should nearly always
be considered for intervention. However, more complex
decision-making processes may be required in select
patient populations, such as those who have asymptomatic
severe VHD, those who are at high risk for intervention,
or those who could beneﬁt from specialized therapies
such as valve repair or transcatheter valve intervention.
The management of patients with complex severe VHD
is best achieved by a Heart Valve Team composed pri-
marily of a cardiologist and surgeon (including a structural
valve interventionist if a catheter-based therapy is being
considered). In selected cases, there may be a multidisci-
plinary, collaborative group of caregivers, including cardi-
ologists, structural valve interventionalists, cardiovascular
imaging specialists, cardiovascular surgeons, anesthesiolo-
gists, and nurses, all of whom have expertise in the man-
agement and outcomes of patients with complex VHD.
The Heart Valve Team should optimize patient selection
for available procedures through a comprehensive under-
standing of the risk–beneﬁt ratio of different treatment
strategies. This is particularly beneﬁcial in patients in whom
there are several options for treatment, such as the elderly
high-risk patient with severe symptomatic aortic stenosis
(AS) being considered for transcatheter aortic valve re-
placement (TAVR) or surgical aortic valve replacement
(AVR). The patient and family should be sufﬁciently
educated by the Heart Valve Team about all alternatives
for treatment so that their expectations can be met as fully
as possible using a shared decision-making approach.
The optimal care of the patient with complex heart
disease is best performed in centers that can provide all
available options for diagnosis and management, including
the expertise for complex aortic or mitral valve repair, aortic
surgery, and transcatheter therapies. This has led to the
development of Heart Valve Centers of Excellence. Heart
Valve Centers of Excellence 1) are composed of experi-
enced healthcare providers with expertise from multiple
disciplines; 2) offer all available options for diagnosis and
management, including complex valve repair, aortic sur-
gery, and transcatheter therapies; 3) participate in regional
or national outcome registries; 4) demonstrate adherence to
national guidelines; 5) participate in continued evaluation
and quality improvement processes to enhance patient
outcomes; and 6) publicly report their available mortality
and success rates. Decisions about intervention at the
Heart Valve Centers of Excellence should be dependent on
the centers’ publicly available mortality rates and operative
outcomes. It is recognized that some Heart Valve Centers
of Excellence may have expertise in select valve problems.
3. Aortic Stenosis: Recommendations
See Table 6 for the stages of valvular AS; Tables 7 and 8 for
a summary of recommendations for choice and timing of
intervention; and Figure 1 for indications for AVR in pa-
tients with AS.3.1. Stages of Valvular AS
Medical and interventional approaches to the management
of patients with valvular AS depend on accurate diagnosis
of the cause and stage of the disease process. Table 6 shows
the stages of AS ranging from patients at risk of AS (stage
A) or with progressive hemodynamic obstruction (stage B)
to severe asymptomatic (stage C) and symptomatic AS
(stage D). Each of these stages is deﬁned by valve anatomy,
valve hemodynamics, the consequences of valve obstruction
on the left ventricle and vasculature, as well as by patient
symptoms. Hemodynamic severity is best characterized by
the transaortic maximum velocity (or mean pressure
gradient) when the transaortic volume ﬂow rate is normal.
However, some patients with AS have a low transaortic
volume ﬂow rate due to either LV systolic dysfunction
with a low left ventricular ejection fraction (LVEF) or due
to a small hypertrophied left ventricle with a low stroke
volume. These categories of severe AS pose a diagnostic
and management challenge distinctly different from the
challenges faced by the majority of patients with AS, who
have a high gradient and velocity when AS is severe. These
special subgroups with low-ﬂow AS are designated D2
(with a low LVEF) and D3 (with a normal LVEF).
The deﬁnition of severe AS is based on natural history
studies of patients with unoperated AS, which show that
the prognosis is poor once there is a peak aortic valve ve-
locity of >4.0 m per second, corresponding to a mean
aortic valve gradient >40 mm Hg. In patients with low
forward ﬂow, severe AS can be present with lower aortic
valve velocities and lower aortic valve gradients. Thus, an
aortic valve area should be calculated in these patients. The
prognosis of patients with AS is poorer when the aortic
valve area is <1.0 cm2. At normal ﬂow rates, an aortic valve
area of <0.8 cm2 correlates with a mean aortic valve
gradient >40 mm Hg. However, symptomatic patients
with a calciﬁed aortic valve with reduced opening and an
aortic valve area between 0.8 cm2 and 1.0 cm2 should be
closely evaluated to determine whether they would beneﬁt
from valve intervention. Meticulous attention to detail is
required when assessing aortic valve hemodynamics, either
with Doppler echocardiography or cardiac catheterization,
and the inherent variability of the measurements and cal-
culations should always be considered in clinical-decision
making.3.2. Diagnosis and Follow-Up
The overall approach to the initial diagnosis of VHD is
discussed in Section 2.3, and additional considerations
speciﬁc to patients with AS are addressed here.
CLASS I
1. TTE is indicated in patients with signs or symptoms of AS or
a bicuspid aortic valve for accurate diagnosis of the cause of
AS, hemodynamic severity, LV size, and systolic function, and
for determining prognosis and timing of valve intervention
(26,27,45). (Level of Evidence: B)
Table 6. Stages of Valvular AS
Stage Deﬁnition Valve Anatomy Valve Hemodynamics Hemodynamic Consequences Symptoms
A At risk of AS  Bicuspid aortic valve (or other
congenital valve anomaly)
 Aortic valve sclerosis
 Aortic Vmax <2 m/s  None  None
B Progressive AS  Mild-to-moderate leaﬂet
calciﬁcation of a bicuspid
or trileaﬂet valve with
some reduction in systolic
motion or
 Rheumatic valve changes
with commissural fusion
 Mild AS:
Aortic Vmax 2.0–2.9 m/s or
mean DP <20 mm Hg
 Moderate AS:
Aortic Vmax 3.0–3.9 m/s or
mean DP 20–39 mm Hg
 Early LV diastolic
dysfunction may
be present
 Normal LVEF
 None
C: Asymptomatic severe AS
C1 Asymptomatic severe
AS
 Severe leaﬂet calciﬁcation
or congenital stenosis with
severely reduced leaﬂet
opening
 Aortic Vmax 4 m/s or
mean DP 40 mm Hg
 AVA typically is 1.0 cm2
(or AVAi 0.6 cm2/m2)
 Very severe AS is an aortic
Vmax 5 m/s or mean
DP 60 mm Hg
 LV diastolic
dysfunction
 Mild LV hypertrophy
 Normal LVEF
 None: Exercise
testing is
reasonable to
conﬁrm
symptom status
C2 Asymptomatic severe
AS with LV
dysfunction
 Severe leaﬂet calciﬁcation
or congenital stenosis with
severely reduced leaﬂet
opening
 Aortic Vmax 4 m/s or
mean DP 40 mm Hg
 AVA typically 1.0 cm2
(or AVAi 0.6 cm2/m2)
 LVEF <50%  None
D: Symptomatic severe AS
D1 Symptomatic severe
high-gradient AS
 Severe leaﬂet calciﬁcation
or congenital stenosis with
severely reduced leaﬂet
opening
 Aortic Vmax 4 m/s or
mean DP 40 mm Hg
 AVA typically 1.0 cm2
(or AVAi 0.6 cm2/m2) but may
be larger with mixed AS/AR
 LV diastolic
dysfunction
 LV hypertrophy
 Pulmonary
hypertension may
be present
 Exertional
dyspnea or
decreased exer-
cise tolerance
 Exertional angina
 Exertional
syncope or
presyncope
D2 Symptomatic severe
low-ﬂow/low-
gradient AS with
reduced LVEF
 Severe leaﬂet calciﬁcation
with severely reduced leaﬂet
motion
 AVA 1.0 cm2 with
resting aortic Vmax <4 m/s or
mean DP <40 mm Hg
 Dobutamine stress echocardiography
shows AVA 1.0 cm2 with
Vmax 4 m/s at any ﬂow rate
 LV diastolic
dysfunction
 LV hypertrophy
 LVEF <50%
 HF
 Angina
 Syncope or
presyncope
D3 Symptomatic severe
low-gradient AS
with normal LVEF or
paradoxical low-ﬂow
severe AS
 Severe leaﬂet calciﬁcation
with severely reduced leaﬂet
motion
 AVA 1.0 cm2 with aortic Vmax
<4 m/s or mean DP <40 mm Hg
 Indexed AVA 0.6 cm2/m2 and
 Stroke volume index <35 mL/m2
 Measured when patient is
normotensive (systolic
BP <140 mm Hg)
 Increased LV relative
wall thickness
 Small LV chamber
with low stroke volume
 Restrictive diastolic
ﬁlling
 LVEF 50%
 HF
 Angina
 Syncope or
presyncope
AR indicates aortic regurgitation; AS, aortic stenosis; AVA, aortic valve area; AVAi, aortic valve area indexed to body surface area; BP, blood pressure; HF, heart failure; LV, left ventricular; LVEF, left
ventricular ejection fraction; DP, pressure gradient; and Vmax, maximum aortic velocity.
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1. Low-dose dobutamine stress testing using echocardiographic or
invasive hemodynamic measurements is reasonable in patients
with stage D2 AS with all of the following (46–48) (Level of
Evidence: B):
a. Calciﬁed aortic valve with reduced systolic opening;
b. LVEF less than 50%;
c. Calculated valve area 1.0 cm2 or less; and
d. Aortic velocity less than 4.0 m per second or mean pressure
gradient less than 40 mm Hg.
2. Exercise testing is reasonable to assess physiological changes
with exercise and to conﬁrm the absence of symptoms in
asymptomatic patients with a calciﬁed aortic valve and an aortic
velocity4.0mper secondor greater ormeanpressuregradient40
mmHg or higher (stage C) (27,37,38,49). (Level of Evidence: B)CLASS III: Harm
1. Exercise testing should not be performed in symptomatic patients
with AS when the aortic velocity is 4.0 m per second or greater or
mean pressure gradient is 40 mm Hg or higher (stage D) (50).
(Level of Evidence: B)3.3. Medical Therapy
CLASS I
1. Hypertension in patients at risk for developing AS
(stage A) and in patients with asymptomatic AS (stages B
and C) should be treated according to standard GDMT,
started at a low dose, and gradually titrated upward as
needed with frequent clinical monitoring (51–53). (Level of
Evidence: B)
Table 7. Summary of Recommendations for AS: Timing of Intervention
Recommendations COR LOE References
AVR is recommended for symptomatic patients with severe high-gradient AS who have
symptoms by history or on exercise testing (stage D1)
I B (10,57–59)
AVR is recommended for asymptomatic patients with severe AS (stage C2) and
LVEF <50%
I B (60,61)
AVR is indicated for patients with severe AS (stage C or D) when undergoing other cardiac
surgery
I B (62,63)
AVR is reasonable for asymptomatic patients with very severe AS (stage C1, aortic
velocity 5.0 m/s) and low surgical risk
IIa B (64,65)
AVR is reasonable in asymptomatic patients (stage C1) with severe AS and decreased exercise
tolerance or an exercise fall in BP
IIa B (27,38)
AVR is reasonable in symptomatic patients with low-ﬂow/low-gradient severe AS with reduced
LVEF (stage D2) with a low-dose dobutamine stress study that shows an aortic
velocity 4.0 m/s (or mean pressure gradient 40 mm Hg) with a valve area 1.0 cm2 at
any dobutamine dose
IIa B (66–68)
AVR is reasonable in symptomatic patients who have low-ﬂow/low-gradient severe AS (stage
D3) who are normotensive and have an LVEF 50% if clinical, hemodynamic, and anatomic
data support valve obstruction as the most likely cause of symptoms
IIa C N/A
AVR is reasonable for patients with moderate AS (stage B) (aortic velocity 3.0–3.9 m/s) who are
undergoing other cardiac surgery
IIa C N/A
AVR may be considered for asymptomatic patients with severe AS (stage C1) and rapid disease
progression and low surgical risk
IIb C N/A
AS indicates aortic stenosis; AVR, aortic valve replacement by either surgical or transcatheter approach; BP, blood pressure; COR, Class of Recommendation; LOE, Level of Evidence; LVEF, left
ventricular ejection fraction; and N/A, not applicable.
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1. Vasodilator therapy may be reasonable if used with invasive
hemodynamic monitoring in the acute management of patients
with severe decompensated AS (stage D) with New York Heart
Association (NYHA) class IV heart failure (HF) symptoms.
(Level of Evidence: C)
CLASS III: No Beneﬁt
1. Statin therapy is not indicated for prevention of hemodynamic
progression of AS in patients with mild-to-moderate calciﬁc
valve disease (stages B to D) (54–56). (Level of Evidence: A)
3.4. Timing of Intervention
See Table 7 for a summary of recommendations from this
section.
CLASS I
1. AVR is recommended in symptomatic patients with severe AS
(stage D1) with (10,57–59) (Level of Evidence: B):
a. Decreased systolic opening of a calciﬁed or congenitally
stenotic aortic valve; and
b. An aortic velocity 4.0 m per second or greater or mean
pressure gradient 40 mm Hg or higher; and
c. Symptoms of HF, syncope, exertional dyspnea, angina, or
presyncope by history or on exercise testing.
2. AVR is recommended for asymptomatic patients with
severe AS (stage C2) and an LVEF less than 50% with
decreased systolic opening of a calciﬁed aortic valve with
an aortic velocity 4.0 m per second or greater or mean
pressure gradient 40 mm Hg or higher (60,61). (Level of
Evidence: B)
3. AVR is indicated for patients with severe AS (stage C or D)
when undergoing cardiac surgery for other indications when
there is decreased systolic opening of a calciﬁed aortic valve
and an aortic velocity 4.0 m per second or greater or mean
pressure gradient 40 mm Hg or higher (62,63). (Level of
Evidence: B)CLASS IIa
1. AVR is reasonable for asymptomatic patients with very severe
AS (stage C1) with (64,65) (Level of Evidence: B):
a. Decreased systolic opening of a calciﬁed valve;
b. An aortic velocity 5.0 m per second or greater or mean
pressure gradient 60 mm Hg or higher; and
c. A low surgical risk.
2. AVR is reasonable in apparently asymptomatic patients with
severe AS (stage C1) with (27,38) (Level of Evidence: B):
a. A calciﬁed aortic valve;
b. An aortic velocity of 4.0 m per second to 4.9 m per second or
mean pressure gradient of 40 mm Hg to 59 mm Hg; and
c. An exercise test demonstrating decreased exercise toler-
ance or a fall in systolic blood pressure (BP).
3. AVR is reasonable in symptomatic patients with low-ﬂow/low-
gradient severe AS with reduced LVEF (stage D2) with a (66–68)
(Level of Evidence: B):
a. Calciﬁed aortic valve with reduced systolic opening;
b. Resting valve area 1.0 cm2 or less;
c. Aortic velocity less than 4.0 m per second or mean pressure
gradient less than 40 mm Hg;
d. LVEF less than 50%; and
e. A low-dose dobutamine stress study that shows an aortic
velocity 4.0 m per second or greater or mean pressure
gradient 40 mm Hg or higher with a valve area 1.0 cm2 or
less at any dobutamine dose.
4. AVR is reasonable in symptomatic patients with low-ﬂow/low-
gradient severe AS (stage D3) with an LVEF 50% or greater, a calci-
ﬁed aortic valve with signiﬁcantly reduced leaﬂet motion, and a valve
area1.0 cm2 or less only if clinical, hemodynamic, and anatomic
data support valve obstruction as the most likely cause of
symptoms and data recorded when the patient is normotensive
(systolic BP <140 mm Hg) indicate (Level of Evidence: C):
a. An aortic velocity less than 4.0 m per second or mean
pressure gradient less than 40 mm Hg; and
b. A stroke volume index less than 35 mL/m2; and
c. An indexed valve area 0.6 cm2/m2 or less.
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24495. AVR is reasonable for patients with moderate AS (stage B) with
an aortic velocity between 3.0 m per second and 3.9 m per
second or mean pressure gradient between 20 mm Hg and 39
mmHg who are undergoing cardiac surgery for other indications.
(Level of Evidence: C)
CLASS IIb
1. AVR may be considered for asymptomatic patients with severe
AS (stage C1) with an aortic velocity 4.0 m per second or
greater or mean pressure gradient 40 mm Hg or higher if the
patient is at low surgical risk and serial testing shows an in-
crease in aortic velocity 0.3 m/s or greater per year. (Level of
Evidence: C)
3.5. Choice of Intervention
See Table 8 for a summary of recommendations from this
section.
CLASS I
1. Surgical AVR is recommended in patients who meet an indication
for AVR (Section 3.4) with low or intermediate surgical risk (Sec-
tion 2.5 in the full-text guideline) (69,70). (Level of Evidence: A)
2. For patients in whom TAVR or high-risk surgical AVR is being
considered, a Heart Valve Team consisting of an integrated,
multidisciplinary group of healthcare professionals with
expertise in VHD, cardiac imaging, interventional cardiology,
cardiac anesthesia, and cardiac surgery should collaborate to
provide optimal patient care. (Level of Evidence: C)
3. TAVR is recommended in patients who meet an indication for
AVR (Section 3.4) who have a prohibitive risk for surgical AVR
(Section 2.5 in the full-text guideline) and a predicted post-
TAVR survival greater than 12 months (71,72). (Level of
Evidence: B)
CLASS IIa
1. TAVR is a reasonable alternative to surgical AVR in patients
who meet an indication for AVR (Section 3.4) and who have
high surgical risk for surgical AVR (Section 2.5 in the full-
text guideline) (73,74). (Level of Evidence: B)
CLASS IIb
1. Percutaneous aortic balloon dilation may be considered as
a bridge to surgical AVR or TAVR in patients with severe
symptomatic AS. (Level of Evidence: C)
CLASS III: No Beneﬁt
1. TAVR is not recommended in patients in whom existing
comorbidities would preclude the expected beneﬁt from
correction of AS (71). (Level of Evidence: B)Table 8. Summary of Recommendations for AS: Choice of Surgical
Recommendations
Surgical AVR is recommended in patients who meet an indication for AVR (Section 3
intermediate surgical risk (Section 2.5 in the full-text guideline)
For patients in whom TAVR or high-risk surgical AVR is being considered, members of a
should collaborate to provide optimal patient care
TAVR is recommended in patients who meet an indication for AVR for AS who have a
risk and a predicted post-TAVR survival >12 mo
TAVR is a reasonable alternative to surgical AVR in patients who meet an indication fo
and who have high surgical risk (Section 2.5 in the full-text guideline)
Percutaneous aortic balloon dilation may be considered as a bridge to surgical or tra
severely symptomatic patients with severe AS
TAVR is not recommended in patients in whom existing comorbidities would preclude
beneﬁt from correction of AS
AS indicates aortic stenosis; AVR, aortic valve replacement; COR, Class of Recommendation; LOE, L4. Aortic Regurgitation: Recommendations
4.1. Stages of Chronic Aortic Regurgitation
The most common causes of chronic aortic regurgitation
(AR) in the United States and other developed
countries are bicuspid aortic valve and calciﬁc valve dis-
ease. In addition, AR frequently arises from primary
diseases causing dilation of the ascending aorta or the
sinuses of Valsalva. Another cause of AR is rheumatic
heart disease (the leading cause in many developing
countries). In the majority of patients with AR, the dis-
ease course is chronic and slowly progressive with
increasing LV volume overload and LV adaptation
via chamber dilation and hypertrophy. Management of
patients with AR depends on accurate diagnosis of
the cause and stage of the disease process. Table 9 shows
the stages of AR ranging from patients at risk of AR
(stage A) or with progressive mild-to-moderate AR
(stage B) to severe asymptomatic (stage C) and symp-
tomatic AR (stage D). Each of these stages is deﬁned
by valve anatomy, valve hemodynamics, severity of LV
dilation, and LV systolic function, as well as by patient
symptoms.
See Figure 2 for indications for AVR for chronic AR.
4.2. Diagnosis and Follow-Up
CLASS I
1. TTE is indicated in patients with signs or symptoms of
AR (stages A to D) for accurate diagnosis of the cause
of regurgitation, regurgitant severity, and LV size and
systolic function, and for determining clinical outcome
and timing of valve intervention (34,75–84). (Level of
Evidence: B)
2. TTE is indicated in patients with dilated aortic sinuses or
ascending aorta or with a bicuspid aortic valve (stages A and B)
to evaluate the presence and severity of AR (85). (Level of
Evidence: B)
3. CMR is indicated in patients with moderate or severe AR
(stages B, C, and D) and suboptimal echocardiographic images
for the assessment of LV systolic function, systolic and dia-
stolic volumes, and measurement of AR severity (86,87). (Level
of Evidence: B)or Transcatheter Intervention
COR LOE References
.4) with low or I A (69,70)
Heart Valve Team I C N/A
prohibitive surgical I B (71,72)
r AVR (Section 3.4) IIa B (73,74)
nscatheter AVR in IIb C N/A
the expected III: No Beneﬁt B (71)
evel of Evidence; N/A, not applicable; and TAVR, transcatheter aortic valve replacement.
Figure 1. Indications for AVR in Patients With AS
Arrows show the decision pathways that result in a recommendation for AVR. Periodic monitoring is indicated for all patients in whom AVR is not yet indicated, including those with
asymptomatic AS (stage D or C) and those with low-gradient AS (stage D2 or D3) who do not meet the criteria for intervention.
*AVR should be considered with stage D3 AS only if valve obstruction is the most likely cause of symptoms, stroke volume index is<35 mL/m2, indexed AVA is 0.6 cm2/m2, and
data are recorded when the patient is normotensive (systolic BP <140 mm Hg).
AS indicates aortic stenosis; AVA; aortic valve area; AVR, aortic valve replacement by either surgical or transcatheter approach; BP, blood pressure; DSE, dobutamine stress
echocardiography; ETT, exercise treadmill test; LVEF, left ventricular ejection fraction; DPmean, mean pressure gradient; and Vmax, maximum velocity.
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24504.3. Medical Therapy
CLASS I
1. Treatment of hypertension (systolic BP >140 mm Hg) is rec-
ommended in patients with chronic AR (stages B and C),
preferably with dihydropyridine calcium channel blockers or
angiotensin-converting enzyme (ACE) inhibitors/angiotensin-
receptor blockers (ARBs) (83,88). (Level of Evidence: B)
CLASS IIa
1. Medical therapy with ACE inhibitors/ARBs and beta blockers is
reasonable in patients with severe AR who have symptoms and/
or LV dysfunction (stages C2 and D) when surgery is not per-
formed because of comorbidities (89,90). (Level of Evidence: B)
4.4. Timing of Intervention
See Table 10 for a summary of recommendations from this
section.CLASS I
1. AVR is indicated for symptomaticpatientswithsevereARregardless
of LVsystolic function (stageD) (33,91,92). (Level of Evidence: B)
2. AVR is indicated for asymptomatic patients with chronic
severe AR and LV systolic dysfunction (LVEF <50%) at rest
(stage C2) if no other cause for systolic dysfunction is
identiﬁed (91,93–95). (Level of Evidence: B)
3. AVR is indicated for patients with severe AR (stage C or D) while un-
dergoing cardiac surgery for other indications. (Level of Evidence: C)
CLASS IIa
1. AVR is reasonable for asymptomatic patientswith severeARwith
normal LV systolic function (LVEF ‡50%) but with severe LV
dilation (LV end-systolic dimension [LVESD] >50 mm or indexed
LVESD >25 mm/m2) (stage C2) (96–98). (Level of Evidence: B)
2. AVR is reasonable in patients with moderate AR (stage B) while
undergoing surgery on the ascending aorta, coronary artery by-
pass graft (CABG), or mitral valve surgery. (Level of Evidence: C)
Table 9. Stages of Chronic AR
Stage Deﬁnition Valve Anatomy Valve Hemodynamics Hemodynamic Consequences Symptoms
A At risk of AR  Bicuspid aortic valve (or other
congenital valve anomaly)
 Aortic valve sclerosis
 Diseases of the aortic
sinuses or ascending aorta
 History of rheumatic fever or
known rheumatic heart disease
 IE
 AR severity: none or trace  None  None
B Progressive AR  Mild-to-moderate
calciﬁcation of a trileaﬂet
valve bicuspid aortic valve
(or other congenital valve
anomaly)
 Dilated aortic sinuses
 Rheumatic valve changes
 Previous IE
 Mild AR:
 Jet width <25% of LVOT;
 Vena contracta <0.3 cm;
 RVol <30 mL/beat;
 RF <30%;
 ERO <0.10 cm2;
 Angiography grade 1þ
 Moderate AR:
 Jet width 25%–64% of LVOT;
 Vena contracta 0.3–0.6 cm;
 RVol 30–59 mL/beat;
 RF 30%–49%;
 ERO 0.10–0.29 cm2;
 Angiography grade 2þ
 Normal LV systolic function
 Normal LV volume or mild
LV dilation
 None
C Asymptomatic
severe AR
 Calciﬁc aortic valve disease
 Bicuspid valve (or other
congenital abnormality)
 Dilated aortic sinuses or
ascending aorta
 Rheumatic valve changes
 IE with abnormal leaﬂet
closure or perforation
 Severe AR:
 Jet width 65% of LVOT;
 Vena contracta >0.6 cm;
 Holodiastolic ﬂow reversal in
the proximal abdominal aorta
 RVol 60 mL/beat;
 RF 50%;
 ERO 0.3 cm2;
 Angiography grade 3þ to 4þ;
 In addition, diagnosis of
chronic severe AR requires
evidence of LV dilation
C1: Normal LVEF (50%) and
mild-to-moderate LV dilation
(LVESD 50 mm)
C2: Abnormal LV systolic
function with depressed LVEF
(<50%) or severe LV
dilatation (LVESD >50 mm or
indexed LVESD >25 mm/m2)
 None; exercise testing is
reasonable to conﬁrm
symptom status
D Symptomatic
severe AR
 Calciﬁc valve disease
 Bicuspid valve (or other
congenital abnormality)
 Dilated aortic sinuses or
ascending aorta
 Rheumatic valve changes
 Previous IE with abnormal
leaﬂet closure or perforation
 Severe AR:
 Doppler jet width65% of LVOT;
 Vena contracta >0.6 cm;
 Holodiastolic ﬂow reversal in
the proximal abdominal aorta;
 RVol 60 mL/beat;
 RF 50%;
 ERO 0.3 cm2;
 Angiography grade 3þ to 4þ;
 In addition, diagnosis of
chronic severe AR requires
evidence of LV dilation
 Symptomatic severe AR may
occur with normal systolic
function (LVEF 50%),
mild-to-moderate LV
dysfunction (LVEF 40%–50%),
or severe LV dysfunction
(LVEF <40%);
 Moderate-to-severe LV
dilation is present
 Exertional dyspnea or
angina or more severe
HF symptoms
AR indicates aortic regurgitation; ERO, effective regurgitant oriﬁce; HF, heart failure; IE, infective endocarditis; LV, left ventricular; LVEF, left ventricular ejection fraction; LVESD, left ventricular
end-systolic dimension; LVOT, left ventricular outﬂow tract; RF, regurgitant fraction; and RVol, regurgitant volume.
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1. AVR may be considered for asymptomatic patients with severe
AR and normal LV systolic function at rest (LVEF ‡50%, stage
C1) but with progressive severe LV dilatation (LV end-diastolic
dimension >65 mm) if surgical risk is low. (Level of Evidence: C)
5. Bicuspid Aortic Valve and Aortopathy:
Recommendations
5.1. Diagnosis and Follow-Up
CLASS I
1. An initial TTE is indicated in patients with a known bicuspid
aortic valve to evaluate valve morphology, to measure the
severity of AS and AR, and to assess the shape and diameter ofthe aortic sinuses and ascending aorta for prediction of clinical
outcome and to determine timing of intervention (99–104).
(Level of Evidence: B)
2. Aortic magnetic resonance angiography or CT angiography is
indicated in patients with a bicuspid aortic valve when
morphology of the aortic sinuses, sinotubular junction, or
ascending aorta cannot be assessed accurately or fully by
echocardiography. (Level of Evidence: C)
3. Serial evaluation of the size andmorphology of the aortic sinuses and
ascending aorta by echocardiography, CMR, or CT angiography is
recommended in patients with a bicuspid aortic valve and an aortic
diameter greater than 4.0 cm, with the examination interval deter-
mined by the degree and rate of progression of aortic dilation and by
familyhistory. Inpatientswithanaortic diametergreater than4.5cm,
this evaluation should be performed annually. (Level of Evidence: C)
Figure 2. Indications for AVR for Chronic AR
AR indicates aortic regurgitation; AVR, aortic valve replacement (valve repair may be appropriate in selected patients); ERO, effective regurgitant oriﬁce; LV, left ventricular;
LVEDD, left ventricular end-diastolic dimension; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic dimension; RF, regurgitant fraction; and RVol,
regurgitant volume.
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24525.2. Intervention
CLASS I
1. Operative intervention to repair the aortic sinuses or replace the
ascending aorta is indicated in patients with a bicuspid aortic
valve if the diameter of the aortic sinuses or ascending aorta is
greater than 5.5 cm (105–107). (Level of Evidence: B)Table 10. Summary of Recommendations for AR Intervention
Recommendations
AVR is indicated for symptomatic patients with severe AR regardless of LV systolic fu
AVR is indicated for asymptomatic patients with chronic severe AR and LV systolic dy
(LVEF <50%) (stage C2)
AVR is indicated for patients with severe AR (stage C or D) while undergoing cardiac
indications
AVR is reasonable for asymptomatic patients with severe AR with normal LV systolic
(LVEF 50%) but with severe LV dilation (LVESD >50 mm, stage C2)
AVR is reasonable in patients with moderate AR (stage B) who are undergoing other
AVR may be considered for asymptomatic patients with severe AR and normal LV sy
(LVEF 50%, stage C1) but with progressive severe LV dilation (LVEDD >65 mm) if s
*Particularly in the setting of progressive LV enlargement.
AR indicates aortic regurgitation; AVR, aortic valve replacement; COR, Class of Recommendation; LOE
ventricular ejection fraction; LVESD, left ventricular end-systolic dimension; and N/A, not applicable.CLASS IIa
1. Operative intervention to repair the aortic sinuses or replace the
ascending aorta is reasonable in patients with bicuspid aortic
valves if the diameter of the aortic sinuses or ascending aorta is
greater than 5.0 cm and a risk factor for dissection is present
(family history of aortic dissection or if the rate of increase in
diameter is ‡0.5 cm per year). (Level of Evidence: C)COR LOE References
nction (stage D) I B (33,91,92)
sfunction I B (91,93–95)
surgery for other I C N/A
function IIa B (96–98)
cardiac surgery IIa C N/A
stolic function
urgical risk is low*
IIb C N/A
, Level of Evidence; LV, left ventricular; LVEDD, left ventricular end-diastolic dimension; LVEF, left
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24532. Replacement of the ascending aorta is reasonable in patients
with a bicuspid aortic valve who are undergoing aortic valve
surgery because of severe AS or AR (Sections 3.4 and 4.4) if
the diameter of the ascending aorta is greater than 4.5 cm.
(Level of Evidence: C)
6. Mitral Stenosis: Recommendations
6.1. Stages of MS
Medical and interventional approaches to the management
of patients with valvular MS depend on accurate diagnosis
of the cause and stage of the disease process. Table 11
shows the stages of mitral valve disease ranging from pa-
tients at risk of MS (stage A) or with progressive hemo-
dynamic obstruction (stage B) to severe asymptomatic
(stage C) and symptomatic MS (stage D). Each of these
stages is deﬁned by valve anatomy, valve hemodynamics,
the consequences of valve obstruction on the left atrium
(LA) and pulmonary circulation, and patient symptoms.
The anatomic features of the stages of MS are based on a
rheumatic etiology for the disease. There are patients who
have a nonrheumatic etiology of MS due to senile calciﬁc
disease (Section 6.3 in the full text) in whom there is a
heavily calciﬁed mitral annulus with extension of the cal-
cium into the leaﬂets. Hemodynamic severity is best
characterized by the planimetered mitral valve area and the
calculated mitral valve area from the diastolic pressure half-
time. The deﬁnition of “severe” MS is based on the severity
at which symptoms occur as well as the severity at which
intervention will improve symptoms. Thus, a mitral valve
area 1.5 cm2 is considered severe. This usually corre-
sponds to a transmitral mean gradient of >5 mm Hg to 10
mm Hg at a normal heart rate. However, the mean pres-
sure gradient is highly dependent on the transvalvular ﬂow
and diastolic ﬁlling period and will vary greatly with
changes in heart rate. The diastolic pressure half-time isTable 11. Stages of MS
Stage Deﬁnition Valve Anatomy Valve He
A At risk of MS  Mild valve doming during diastole  Normal transm
B Progressive MS  Rheumatic valve changes with
commissural fusion and diastolic
doming of the mitral valve leaﬂets
 Planimetered MVA >1.5 cm2
 Increased trans
 MVA >1.5 cm2
 Diastolic pressu
C Asymptomatic
severe MS
 Rheumatic valve changes with
commissural fusion and diastolic
doming of the mitral valve leaﬂets
 Planimetered MVA 1.5 cm2
 (MVA 1.0 cm2 with very
severe MS)
 MVA 1.5 cm2
 (MVA 1.0 cm2
 Diastolic pressu
 (Diastolic press
with very sever
D Symptomatic
severe MS
 Rheumatic valve changes with
commissural fusion and diastolic
doming of the mitral valve leaﬂets
 Planimetered MVA 1.5 cm2
 MVA 1.5 cm2
 (MVA 1.0 cm2
 Diastolic pressu
 (Diastolic press
220 ms with
The transmitral mean pressure gradient should be obtained to further determine the hemodynamic effect
the mean pressure gradient with heart rate and forward ﬂow, it has not been included in the criteria fo
LA indicates left atrial; LV, left ventricular; MS, mitral stenosis; MVA, mitral valve area; and PASP, pdependent not only on the degree of mitral obstruction but
also the compliance of the left ventricle and LA and other
measures of mitral valve area, such as the continuity
equation or the proximal isovelocity surface area, may be
used if discrepancies exist.
Supporting References: (108–114)
See Figure 3 for indications for intervention for
rheumatic MS.
6.2. Diagnosis and Follow-Up
CLASS I
1. TTE is indicated in patients with signs or symptoms of MS to
establish the diagnosis, quantify hemodynamic severity (mean
pressure gradient, mitral valve area, and pulmonary artery pres-
sure), assess concomitant valvular lesions, and demonstrate
valve morphology (to determine suitability for mitral commissur-
otomy) (9,115–123). (Level of Evidence: B)
2. TEE should be performed in patients considered for percuta-
neous mitral balloon commissurotomy to assess the presence
or absence of left atrial thrombus and to further evaluate the
severity of mitral regurgitation (MR) (116,124–126). (Level of
Evidence: B)
3. Exercise testing with Doppler or invasive hemodynamic assess-
ment is recommended to evaluate the response of themeanmitral
gradient and pulmonary artery pressure in patients with MS when
there is a discrepancy between restingDoppler echocardiographic
ﬁndings and clinical symptoms or signs. (Level of Evidence: C)
6.3. Medical Therapy
CLASS I
1. Anticoagulation (vitamin K antagonist [VKA] or heparin) is
indicated in patients with 1) MS and AF (paroxysmal, persis-
tent, or permanent), 2) MS and a prior embolic event, or 3) MS
and a left atrial thrombus (127–133). (Level of Evidence: B)
CLASS IIa
1. Heart rate control can be beneﬁcial in patients with MS and AF
and fast ventricular response. (Level of Evidence: C)modynamics
Hemodynamic
Consequences Symptoms
itral ﬂow velocity None  None
mitral ﬂow velocities
re half-time <150 ms
 Mild-to-moderate LA
enlargement
 Normal pulmonary
pressure at rest
 None
with very severe MS)
re half-time 150 ms
ure half-time 220 ms
e MS)
 Severe LA enlargement
 Elevated PASP
>30 mm Hg
 None
with very severe MS)
re half-time 150 ms
ure half-time
very severe MS)
 Severe LA enlargement
 Elevated PASP
>30 mm Hg
 Decreased exercise
tolerance
 Exertional dyspnea
of the MS and is usually >5 mm Hg to 10 mm Hg in severe MS; however, due to the variability of
r severity.
ulmonary artery systolic pressure.
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1. Heart rate control may be considered for patients with MS
in normal sinus rhythm and symptoms associated with exercise
(134,135). (Level of Evidence: B)6.4. Intervention
See Table 12 for a summary of recommendations from this
section.
CLASS I
1. Percutaneous mitral balloon commissurotomy is recommended
for symptomatic patients with severe MS (mitral valve
area £1.5 cm2, stage D) and favorable valve morphology in the
absence of left atrial thrombus or moderate-to-severe MR
(108–112,114,136). (Level of Evidence: A)
2. Mitral valve surgery (repair, commissurotomy, or valve
replacement) is indicated in severely symptomatic patients
(NYHA class III to IV) with severe MS (mitral valve
area £1.5 cm2, stage D) who are not high risk for surgery and
who are not candidates for or who have failed previous percu-
taneous mitral balloon commissurotomy (137–142). (Level of
Evidence: B)Figure 3. Indications for Intervention for Rheumatic MS
AF indicates atrial ﬁbrillation; LA, left atrial; MR, mitral regurgitation; MS, mitral stenosis;
York Heart Association; PCWP, pulmonary capillary wedge pressure; PMBC, percutaneous3. Concomitant mitral valve surgery is indicated for patients with
severe MS (mitral valve area £1.5 cm2, stage C or D) under-
going cardiac surgery for other indications. (Level of Evidence: C)
CLASS IIa
1. Percutaneous mitral balloon commissurotomy is reasonable for
asymptomatic patients with very severe MS (mitral valve
area £1.0 cm2, stage C) and favorable valve morphology in the
absence of left atrial thrombus or moderate-to-severe MR
(121,143–145). (Level of Evidence: C)
2. Mitral valve surgery is reasonable for severely symptomatic
patients (NYHA class III to IV) with severe MS (mitral valve
area £1.5 cm2, stage D), provided there are other operative
indications (e.g., aortic valve disease, coronary artery disease
(CAD), tricuspid regurgitation (TR), aortic aneurysm). (Level of
Evidence: C)
CLASS IIb
1. Percutaneous mitral balloon commissurotomy may be consid-
ered for asymptomatic patients with severe MS (mitral valve
area £1.5 cm2, stage C) and valve morphology favorable for
percutaneous mitral balloon commissurotomy in the absence of
left atrial thrombus or moderate-to-severe MR who have new
onset of AF. (Level of Evidence: C)MVA, mitral valve area; MVR, mitral valve surgery (repair or replacement); NYHA, New
mitral balloon commissurotomy; and T 1/2, pressure half-time.
Table 12. Summary of Recommendations for MS Intervention
Recommendations COR LOE References
PMBC is recommended for symptomatic patients with severe MS (MVA 1.5 cm2, stage D) and
favorable valve morphology in the absence of contraindications
I A (108–112,114)
Mitral valve surgery is indicated in severely symptomatic patients (NYHA class III/IV) with severe MS
(MVA 1.5 cm2, stage D) who are not high risk for surgery and who are not candidates for or failed
previous PMBC
I B (137–142)
Concomitant mitral valve surgery is indicated for patients with severe MS (MVA 1.5 cm2, stage
C or D) undergoing other cardiac surgery
I C N/A
PMBC is reasonable for asymptomatic patients with very severe MS (MVA 1.0 cm2, stage C) and
favorable valve morphology in the absence of contraindications
IIa C (121,143–145)
Mitral valve surgery is reasonable for severely symptomatic patients (NYHA class III/IV) with severe
MS (MVA 1.5 cm2, stage D), provided there are other operative indications
IIa C N/A
PMBC may be considered for asymptomatic patients with severe MS (MVA 1.5 cm2, stage C) and
favorable valve morphology who have new onset of AF in the absence of contraindications
IIb C N/A
PMBC may be considered for symptomatic patients with MVA >1.5 cm2 if there is evidence of
hemodynamically signiﬁcant MS during exercise
IIb C N/A
PMBC may be considered for severely symptomatic patients (NYHA class III/IV) with severe MS
(MVA 1.5 cm2, stage D) who have suboptimal valve anatomy and are not candidates for surgery
or at high risk for surgery
IIb C N/A
Concomitant mitral valve surgery may be considered for patients with moderate MS
(MVA 1.6–2.0 cm2) undergoing other cardiac surgery
IIb C N/A
Mitral valve surgery and excision of the left atrial appendage may be considered for patients with
severe MS (MVA 1.5 cm2, stages C and D) who have had recurrent embolic events while receiving
adequate anticoagulation
IIb C N/A
AF indicates atrial ﬁbrillation; COR, Class of Recommendation; LOE, Level of Evidence; MS, mitral stenosis; MVA, mitral valve area; NYHA, New York Heart Association; and PMBC, percutaneous mitral
balloon commissurotomy.
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24552. Percutaneous mitral balloon commissurotomy may be consid-
ered for symptomatic patients with mitral valve area greater
than 1.5 cm2 if there is evidence of hemodynamically signiﬁcant
MS based on pulmonary artery wedge pressure greater than 25
mm Hg or mean mitral valve gradient greater than 15 mm Hg
during exercise. (Level of Evidence: C)
3. Percutaneous mitral balloon commissurotomy may be consid-
ered for severely symptomatic patients (NYHA class III to IV)
with severe MS (mitral valve area £1.5 cm2, stage D) who have
a suboptimal valve anatomy and who are not candidates for
surgery or at high risk for surgery. (Level of Evidence: C)
4. Concomitant mitral valve surgery may be considered for pa-
tients with moderate MS (mitral valve area 1.6 cm2 to 2.0 cm2)
undergoing cardiac surgery for other indications. (Level of
Evidence: C)
5. Mitral valve surgery and excision of the left atrial appendage
may be considered for patients with severe MS (mitral valve
area £1.5 cm2, stages C and D) who have had recurrent embolic
events while receiving adequate anticoagulation. (Level of
Evidence: C)
7. Mitral Regurgitation: Recommendations
7.1. Stages of Chronic MR
In assessing the patient with chronic MR, it is critical to
distinguish between chronic primary (degenerative) MR
and chronic secondary (functional) MR, as these 2 condi-
tions have more differences than similarities.
In chronic primary MR, the pathology of 1 of the
components of the valve (leaﬂets, chordae tendineae,
papillary muscles, annulus) causes valve incompetence with
systolic regurgitation of blood from the left ventricle to the
LA (Table 13). The most common cause of chronicprimary MR in developed countries is mitral valve pro-
lapse, which has a wide spectrum of etiology and pre-
sentation. Younger populations present with severe
myxomatous degeneration with gross redundancy of both
anterior and posterior leaﬂets and the chordal apparatus
(Barlow’s valve). Alternatively, older populations present
with ﬁbroelastic deﬁciency disease, in which lack of con-
nective tissue leads to chordal rupture. The differentiation
between these 2 etiologies has important implications
for operative intervention. Other less common causes of
chronic primary MR include IE, connective tissue disor-
ders, rheumatic heart disease, cleft mitral valve, and radi-
ation heart disease. If the subsequent volume overload of
chronic primary MR is prolonged and severe, it causes
myocardial damage, HF, and eventual death. Correction of
the MR is curative. Thus, MR is “the disease.”
In chronic secondary MR, the mitral valve is usually
normal (Table 14). Instead, severe LV dysfunction is caused
either by CAD, related myocardial infarction (ischemic
chronic secondary MR), or idiopathic myocardial disease
(nonischemic chronic secondary MR). The abnormal and
dilated left ventricle causes papillary muscle displacement,
which in turn results in leaﬂet tethering with associated
annular dilation that prevents coaptation. Because MR is
only 1 component of the disease (severe LV dysfunction,
coronary disease, or idiopathic myocardial disease are the
others), restoration of mitral valve competence is not by
itself curative; thus, the best therapy for chronic secondary
MR is much less clear than it is for chronic primary MR.
The data are limited, and there is greater difﬁculty in
deﬁning the severity of MR in patients with secondary MR
than in those with primary MR. In patients with secondary
Table 13. Stages of Primary MR
Grade Deﬁnition Valve Anatomy Valve Hemodynamics* Hemodynamic Consequences Symptoms
A At risk of MR  Mild mitral valve prolapse with
normal coaptation
 Mild valve thickening and leaﬂet
restriction
 No MR jet or small central jet
area <20% LA on Doppler
 Small vena contracta <0.3 cm
 None  None
B Progressive MR  Severe mitral valve prolapse with
normal coaptation
 Rheumatic valve changes with
leaﬂet restriction and loss of
central coaptation
 Prior IE
 Central jet MR 20%–40% LA or
late systolic eccentric jet MR
 Vena contracta <0.7 cm
 Regurgitant volume <60 mL
 Regurgitant fraction <50%
 ERO <0.40 cm2
 Angiographic grade 1–2þ
 Mild LA enlargement
 No LV enlargement
 Normal pulmonary pressure
 None
C Asymptomatic
severe MR
 Severe mitral valve prolapse
with loss of coaptation or
ﬂail leaﬂet
 Rheumatic valve changes with
leaﬂet restriction and loss of
central coaptation
 Prior IE
 Thickening of leaﬂets with
radiation heart disease
 Central jet MR >40% LA or
holosystolic eccentric jet MR
 Vena contracta 0.7 cm
 Regurgitant volume 60 mL
 Regurgitant fraction 50%
 ERO 0.40 cm2
 Angiographic grade 3–4þ
 Moderate or severe LA
enlargement
 LV enlargement
 Pulmonary hypertension may
be present at rest or with exercise
 C1: LVEF >60% and LVESD <40 mm
 C2: LVEF 60% and LVESD 40 mm
 None
D Symptomatic
severe MR
 Severe mitral valve prolapse with
loss of coaptation or ﬂail leaﬂet
 Rheumatic valve changes with
leaﬂet restriction and loss of
central coaptation
 Prior IE
 Thickening of leaﬂets with
radiation heart disease
 Central jet MR >40% LA or
holosystolic eccentric jet MR
 Vena contracta 0.7 cm
 Regurgitant volume 60 mL
 Regurgitant fraction 50%
 ERO 0.40 cm2
 Angiographic grade 3–4þ
 Moderate or severe LA
enlargement
 LV enlargement
 Pulmonary hypertension present
 Decreased
exercise
tolerance
 Exertional
dyspnea
*Several valve hemodynamic criteria are provided for assessment of MR severity, but not all criteria for each category will be present in each patient. Categorization of MR severity as mild, moderate, or
severe depends on data quality and integration of these parameters in conjunction with other clinical evidence.
ERO indicates effective regurgitant oriﬁce; IE, infective endocarditis; LA, left atrium/atrial; LV, left ventricular; LVEF, left ventricular ejection fraction; LVESD; left ventricular end-systolic dimension; and
MR, mitral regurgitation.
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2456MR, adverse outcomes are associated with a smaller
calculated effective regurgitant oriﬁce compared to primary
MR due to multiple reasons. The MR will likely progress
due to the associated progressive LV systolic dysfunction
and adverse remodeling. In addition, there is an underesti-
mation of effective regurgitant oriﬁce area by the 2-dimen-
sional echocardiographyderived ﬂow convergence method
due to the crescentic shape of the regurgitant oriﬁce. There
are the additional clinical effects of a smaller amount of
regurgitation in the presence of compromised LV systolic
function and baseline elevated ﬁlling pressures.
7.2. Chronic Primary MR
7.2.1. Diagnosis and Follow-Up
CLASS I
1. TTE is indicated for baseline evaluation of LV size and function,
right ventricular (RV) function and left atrial size, pulmonary
artery pressure, and mechanism and severity of primary MR
(stages A to D) in any patient suspected of having chronic
primary MR (6,23,146–162). (Level of Evidence: B)
2. CMR is indicated in patients with chronic primary MR to
assess LV and RV volumes, function, or MR severity and
when these issues are not satisfactorily addressed by TTE
(157,163,164). (Level of Evidence: B)
3. Intraoperative TEE is indicated to establish the anatomic basis
for chronic primary MR (stages C and D) and to guide repair
(165,166). (Level of Evidence: B)4. TEE is indicated for evaluation of patients with chronic primary
MR (stages B to D) in whom noninvasive imaging provides
nondiagnostic information about severity of MR, mechanism of
MR, and/or status of LV function. (Level of Evidence: C)CLASS IIa
1. Exercise hemodynamics with either Doppler echocardiography
or cardiac catheterization is reasonable in symptomatic pa-
tients with chronic primary MR where there is a discrepancy
between symptoms and the severity of MR at rest (stages B
and C) (167,168). (Level of Evidence: B)
2. Exercise treadmill testing can be useful in patients with chronic
primary MR to establish symptom status and exercise tolerance
(stages B and C). (Level of Evidence: C)7.2.2. Medical Therapy
CLASS IIa
1. Medical therapy for systolic dysfunction is reasonable in
symptomatic patients with chronic primary MR (stage D) and
LVEF less than 60% in whom surgery is not contemplated
(169–173). (Level of Evidence: B)
CLASS III: No Beneﬁt
1. Vasodilator therapy is not indicated for normotensive asymp-
tomatic patients with chronic primary MR (stages B and C1) and
normal systolic LV function (173–178). (Level of Evidence: B)
7.2.3. Intervention
See Table 15 for a summary of recommendations from this
section.
Table 14. Stages of Secondary MR
Grade Deﬁnition Valve Anatomy Valve Hemodynamics* Associated Cardiac Findings Symptoms
A At risk of MR  Normal valve leaﬂets, chords,
and annulus in a patient with
coronary disease or
cardiomyopathy
 No MR jet or small central
jet area <20% LA on Doppler
 Small vena contracta
<0.30 cm
 Normal or mildly dilated LV
size with ﬁxed (infarction) or
inducible (ischemia) regional
wall motion abnormalities
 Primary myocardial disease
with LV dilation and systolic
dysfunction
 Symptoms due to coronary
ischemia or HF may be pre-
sent that respond to revascu-
larization and appropriate
medical therapy
B Progressive MR  Regional wall motion abnor-
malities with mild tethering
of mitral leaﬂet
 Annular dilation with mild
loss of central coaptation of
the mitral leaﬂets
 ERO <0.20 cm2y
 Regurgitant volume <30 mL
 Regurgitant fraction <50%
 Regional wall motion abnor-
malities with reduced LV
systolic function
 LV dilation and systolic
dysfunction due to primary
myocardial disease
 Symptoms due to coronary
ischemia or HF may be pre-
sent that respond to revascu-
larization and appropriate
medical therapy
C Asymptomatic
severe MR
 Regional wall motion abnor-
malities and/or LV dilation
with severe tethering of
mitral leaﬂet
 Annular dilation with severe
loss of central coaptation of
the mitral leaﬂets
 ERO 0.20 cm2y
 Regurgitant volume 30 mL
 Regurgitant fraction 50%
 Regional wall motion abnor-
malities with reduced LV
systolic function
 LV dilation and systolic
dysfunction due to primary
myocardial disease
 Symptoms due to coronary
ischemia or HF may be pre-
sent that respond to revascu-
larization and appropriate
medical therapy
D Symptomatic
severe MR
 Regional wall motion abnor-
malities and/or LV dilation
with severe tethering of
mitral leaﬂet
 Annular dilation with severe
loss of central coaptation of
the mitral leaﬂets
 ERO 0.20 cm2y
 Regurgitant volume 30 mL
 Regurgitant fraction 50%
 Regional wall motion abnor-
malities with reduced LV
systolic function
 LV dilation and systolic
dysfunction due to primary
myocardial disease
 HF symptoms due to MR
persist even after revasculari-
zation and optimization of
medical therapy
 Decreased exercise tolerance
 Exertional dyspnea
*Several valve hemodynamic criteria are provided for assessment of MR severity, but not all criteria for each category will be present in each patient. Categorization of MR severity as mild, moderate,
or severe depends on data quality and integration of these parameters in conjunction with other clinical evidence.
yThe measurement of the proximal isovelocity surface area by 2D TTE in patients with secondary MR underestimates the true ERO due to the crescentic shape of the proximal convergence.
2D indicates 2-dimensional; ERO, effective regurgitant oriﬁce; HF, heart failure; LA, left atrium; LV, left ventricular; MR, mitral regurgitation; and TTE, transthoracic echocardiogram.
JACC Vol. 63, No. 22, 2014 Nishimura et al.
June 10, 2014:2438–88 2014 AHA/ACC Valvular Heart Disease Guideline: Executive Summary
2457CLASS I
1. Mitral valve surgery is recommended for symptomatic patients
with chronic severe primary MR (stage D) and LVEF greater
than 30% (156,179). (Level of Evidence: B)
2. Mitral valve surgery is recommended for asymptomatic patients
with chronic severe primary MR and LV dysfunction (LVEF 30%
to 60% and/or LVESD ‡40 mm, stage C2) (150–153,180–182).
(Level of Evidence: B)
3. Mitral valve repair is recommended in preference to mitral valve
replacement (MVR) when surgical treatment is indicated for
patients with chronic severe primary MR limited to the posterior
leaﬂet (155,183–198). (Level of Evidence: B)
4. Mitral valve repair is recommended in preference to MVR when
surgical treatment is indicated for patients with chronic severe
primary MR involving the anterior leaﬂet or both leaﬂets when a
successful and durable repair can be accomplished
(195–197,199–203). (Level of Evidence: B)
5. Concomitant mitral valve repair or MVR is indicated in patients
with chronic severe primary MR undergoing cardiac surgery for
other indications (204). (Level of Evidence: B)
CLASS IIa
1. Mitral valve repair is reasonable in asymptomatic patients with
chronic severe primary MR (stage C1) with preserved LV
function (LVEF >60% and LVESD <40 mm) in whom the likeli-
hood of a successful and durable repair without residual MR is
greater than 95% with an expected mortality rate of less than
1% when performed at a Heart Valve Center of Excellence
(149,203,205–209). (Level of Evidence: B)2. Mitral valve repair is reasonable for asymptomatic pati-
ents with chronic severe nonrheumatic primary MR (stage
C1) and preserved LV function (LVEF >60% and LVESD
<40 mm) in whom there is a high likelihood of a success-
ful and durable repair with 1) new onset of AF or 2)
resting pulmonary hypertension (pulmonary artery systolic
arterial pressure >50 mm Hg) (154,205,210–215). (Level of
Evidence: B)
3. Concomitant mitral valve repair is reasonable in patients
with chronic moderate primary MR (stage B) when under-
going cardiac surgery for other indications. (Level of
Evidence: C)
CLASS IIb
1. Mitral valve surgery may be considered in symptomatic patients
with chronic severe primary MR and LVEF less than or equal to
30% (stage D). (Level of Evidence: C)
2. Mitral valve repair may be considered in patients with rheumatic
mitral valve disease when surgical treatment is indicated
if a durable and successful repair is likely or when the reliability
of long-term anticoagulation management is questionable
(194,202,203). (Level of Evidence: B)
3. Transcatheter mitral valve repair may be considered for
severely symptomatic patients (NYHA class III to IV) with
chronic severe primary MR (stage D) who have favorable
anatomy for the repair procedure and a reasonable life ex-
pectancy but who have a prohibitive surgical risk because
of severe comorbidities and remain severely symptomatic
despite optimal GDMT for HF (216). (Level of Evidence: B)
Table 15. Summary of Recommendations for Chronic Primary MR
Recommendations COR LOE References
MV surgery is recommended for symptomatic patients with chronic severe primary MR
(stage D) and LVEF >30%
I B (156,179)
MV surgery is recommended for asymptomatic patients with chronic severe primary MR
and LV dysfunction (LVEF 30%–60% and/or LVESD 40 mm, stage C2)
I B (150–153,180–182)
MV repair is recommended in preference to MVR when surgical treatment is indicated for
patients with chronic severe primary MR limited to the posterior leaﬂet
I B (155,183–198)
MV repair is recommended in preference to MVR when surgical treatment is indicated for
patients with chronic severe primary MR involving the anterior leaﬂet or both leaﬂets
when a successful and durable repair can be accomplished
I B (195–197,199–203)
Concomitant MV repair or replacement is indicated in patients with chronic severe primary
MR undergoing cardiac surgery for other indications
I B (204)
MV repair is reasonable in asymptomatic patients with chronic severe primary MR
(stage C1) with preserved LV function (LVEF >60% and LVESD <40 mm) in whom the
likelihood of a successful and durable repair without residual MR is >95% with an
expected mortality rate of <1% when performed at a Heart Valve Center of Excellence
IIa B (149,203,205–209)
MV repair is reasonable for asymptomatic patients with chronic severe nonrheumatic
primary MR (stage C1) and preserved LV function in whom there is a high likelihood of a
successful and durable repair with 1) new onset of AF or 2) resting pulmonary
hypertension (PA systolic arterial pressure >50 mm Hg)
IIa B (154,205,210–215)
Concomitant MV repair is reasonable in patients with chronic moderate primary MR
(stage B) undergoing cardiac surgery for other indications
IIa C N/A
MV surgery may be considered in symptomatic patients with chronic severe primary MR
and LVEF 30% (stage D)
IIb C N/A
MV repair may be considered in patients with rheumatic mitral valve disease when surgical
treatment is indicated if a durable and successful repair is likely or if the reliability of
long-term anticoagulation management is questionable
IIb B (194,202,203)
Transcatheter MV repair may be considered for severely symptomatic patients (NYHA class
III/IV) with chronic severe primary MR (stage D) who have a reasonable life expectancy
but a prohibitive surgical risk because of severe comorbidities
IIb B (216)
MVR should not be performed for treatment of isolated severe primary MR limited to less
than one half of the posterior leaﬂet unless MV repair has been attempted and was
unsuccessful
III: Harm B (195–198)
AF indicates atrial ﬁbrillation; COR, Class of Recommendation; LOE, Level of Evidence; LV, left ventricular; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic dimension; MR,
mitral regurgitation; MV, mitral valve; MVR, mitral valve replacement; N/A, not applicable; NYHA, New York Heart Association; and PA, pulmonary artery.
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1. MVR should not be performed for the treatment of isolated se-
vere primary MR limited to less than one half of the posterior
leaﬂet unless mitral valve repair has been attempted and was
unsuccessful (195–198). (Level of Evidence: B)7.3. Chronic Secondary MR
7.3.1. Diagnosis and Follow-Up
CLASS I
1. TTE is useful to establish the etiology of chronic secondary MR
(stages B to D) and the extent and location of wall motion
abnormalities and to assess global LV function, severity of MR,
and magnitude of pulmonary hypertension. (Level of Evidence: C)
2. Noninvasive imaging (stress nuclear/positron emission tomogra-
phy,CMR,orstressechocardiography), cardiacCTangiography, or
cardiac catheterization, including coronary arteriography, is useful
to establish etiology of chronic secondary MR (stages B to D)
and/or to assess myocardial viability, which in turn may inﬂuence
management of functional MR. (Level of Evidence: C)
7.3.2. Medical Therapy
CLASS I
1. Patients with chronic secondary MR (stages B to D) and HF
with reduced LVEF should receive standard GDMT therapy for
HF, including ACE inhibitors, ARBs, beta blockers, and/or
aldosterone antagonists as indicated (128,217–221). (Level of
Evidence: A)2. Cardiac resynchronization therapy with biventricular pacing is
recommended for symptomatic patients with chronic severe
secondary MR (stages B to D) who meet the indications for de-
vice therapy (222,223). (Level of Evidence: A)
7.3.3. Intervention
See Table 16 for a summary of recommendations for this
section and Figure 4 for indications for surgery for MR.
CLASS IIa
1. Mitral valve surgery is reasonable for patients with chronic
severe secondary MR (stages C and D) who are undergoing
CABG or AVR. (Level of Evidence: C)
CLASS IIb
1. Mitral valve repair or replacement may be considered for severely
symptomatic patients (NYHA class III to IV) with chronic severe
secondary MR (stage D) who have persistent symptoms despite
optimal GDMT for HF (224–235). (Level of Evidence: B)
2. Mitral valve repair may be considered for patients with chronic
moderate secondary MR (stage B) who are undergoing other
cardiac surgery. (Level of Evidence: C)
8. Tricuspid Valve Disease:
Recommendations
8.1. Stages of TRTrace-to-mild degrees of TR of no physiological conse-
quence are commonly detected on TTE in subjects with
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tricuspid apparatus that can lead to more signiﬁcant degrees
of TR include rheumatic disease, prolapse, congenital dis-
ease (Ebstein’s), IE, radiation, carcinoid, blunt chest wall
trauma, RV endomyocardial biopsy–related trauma, and
intra-annular RV pacemaker or implantable cardioverter-
deﬁbrillator leads. Approximately 80% of cases of signiﬁ-
cant TR are functional in nature and related to tricuspid
annular dilation and leaﬂet tethering in the setting of RV
remodeling due to pressure and/or volume overload. The
tricuspid annulus is a saddle-shaped ellipsoid that becomes
planar and circular as it dilates in an anterior-posterior di-
rection and will often not return to its normal size and
conﬁguration after relief of RV overload. Table 17 shows the
stages (A through D) of primary and functional TR as
deﬁned for other valve lesions. Severe TR (stages C and D)
is associated with poor prognosis independent of age, LV
and RV function, and RV size. Patients with signs or
symptoms of right HF would ﬁt into the stage D category
even if they do not meet other hemodynamic or morpho-
logical criteria.
Supporting Reference: (236)8.2. Tricuspid Regurgitation
See Figure 5 for indications for surgery.
8.2.1. Diagnosis and Follow-Up
CLASS I
1. TTE is indicated to evaluate severity of TR, determine etiology,
measure sizes of right-sided chambers and inferior vena cava,
assess RV systolic function, estimate pulmonary artery systolic
pressure, and characterize any associated left-sided heart dis-
ease. (Level of Evidence: C)
CLASS IIa
1. Invasive measurement of pulmonary artery pressures and pul-
monary vascular resistance can be useful in patients with TR
when clinical and noninvasive data regarding their values are
discordant. (Level of Evidence: C)
CLASS IIb
1. CMR or real-time 3-dimensional echocardiography may be
considered for assessment of RV systolic function and systolic
and diastolic volumes in patients with severe TR (stages C and
D) and suboptimal 2-dimensional echocardiograms. (Level of
Evidence: C)Table 16. Summary of Recommendations for Chronic Severe Secon
Recommendations
MV surgery is reasonable for patients with chronic severe secondary MR (stages C and
are undergoing CABG or AVR
MV surgery may be considered for severely symptomatic patients (NYHA class III/IV)
chronic severe secondary MR (stage D)
MV repair may be considered for patients with chronic moderate secondary MR (stag
are undergoing other cardiac surgery
AVR indicates aortic valve replacement; CABG, coronary artery bypass graft; COR, Class of Recommend
NYHA, New York Heart Association.2. Exercise testing may be considered for the assessment
of exercise capacity in patients with severe TR with no or
minimal symptoms (stage C). (Level of Evidence: C)
8.2.2. Medical Therapy
CLASS IIa
1. Diuretics can be useful for patients with severe TR and signs
of right-sided HF (stage D). (Level of Evidence: C)
CLASS IIb
1. Medical therapies to reduce elevated pulmonary artery pres-
sures and/or pulmonary vascular resistance might be
considered in patients with severe functional TR (stages C
and D). (Level of Evidence: C)
8.2.3. Intervention
CLASS I
1. Tricuspid valve surgery is recommended for patients with se-
vere TR (stages C and D) undergoing left-sided valve surgery.
(Level of Evidence: C)
CLASS IIa
1. Tricuspid valve repair can be beneﬁcial for patients with mild,
moderate, or greater functional TR (stage B) at the time of
left-sided valve surgery with either 1) tricuspid annular dila-
tion or 2) prior evidence of right HF (237–246). (Level of
Evidence: B)
2. Tricuspid valve surgery can be beneﬁcial for patients with
symptoms due to severe primary TR that are unresponsive to
medical therapy (stage D). (Level of Evidence: C)
CLASS IIb
1. Tricuspid valve repair may be considered for patients withmoderate
functional TR (stage B) and pulmonary artery hypertension at the
time of left-sided valve surgery. (Level of Evidence: C)
2. Tricuspid valve surgery may be considered for asymptomatic or
minimally symptomatic patients with severe primary TR (stage
C) and progressive degrees of moderate or greater RV dilation
and/or systolic dysfunction. (Level of Evidence: C)
3. Reoperation for isolated tricuspid valve repair or replacement
may be considered for persistent symptoms due to severe TR
(stage D) in patients who have undergone previous left-sided
valve surgery and who do not have severe pulmonary hyper-
tension or signiﬁcant RV systolic dysfunction. (Level of
Evidence: C)8.3. Stages of Tricuspid Stenosis
See Table 18 for the stages of severe tricuspid stenosis (TS).dary MR
COR LOE References
D) who IIa C N/A
with IIb B (224–235)
e B) who IIb C N/A
ation; LOE, Level of Evidence; MR, mitral regurgitation; MV, mitral valve; N/A, not applicable; and
Figure 4. Indications for Surgery for MR
*Mitral valve repair is preferred over MVR when possible.
AF indicates atrial ﬁbrillation; CAD, coronary artery disease; CRT, cardiac resynchronization therapy; ERO, effective regurgitant oriﬁce; HF, heart failure; LV, left ventricular; LVEF,
left ventricular ejection fraction; LVESD, left ventricular end-systolic dimension; MR, mitral regurgitation, MV, mitral valve; MVR, mitral valve replacement; NYHA, New York Heart
Association; PASP, pulmonary artery systolic pressure; RF, regurgitant fraction; RVol, regurgitant volume; and Rx, therapy.
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24608.4. Tricuspid Stenosis
8.4.1. Diagnosis and Follow-Up
CLASS I
1. TTE is indicated in patients with TS to assess the anatomy of
the valve complex, evaluate severity of stenosis, and charac-
terize any associated regurgitation and/or left-sided valve
disease. (Level of Evidence: C)
CLASS IIb
1. Invasive hemodynamic assessment of severity of TS may be
considered in symptomatic patients when clinical and nonin-
vasive data are discordant. (Level of Evidence: C)
8.4.2. Intervention
CLASS I
1. Tricuspid valve surgery is recommended for patients with se-
vere TS at the time of operation for left-sided valve disease.
(Level of Evidence: C)
2. Tricuspid valve surgery is recommended for patients with iso-
lated, symptomatic severe TS. (Level of Evidence: C)CLASS IIb
1. Percutaneous balloon tricuspid commissurotomy might be
considered in patients with isolated, symptomatic severe TS
without accompanying TR. (Level of Evidence: C)9. Stages of Pulmonic Valve Disease
See Table 19 for the stages of severe pulmonic regurgita-
tion and Table 20 for the stages of severe pulmonic stenosis.
10. Prosthetic Valves: Recommendations
10.1. Evaluation and Selection
of Prosthetic Valves
10.1.1. Diagnosis and Follow-Up
CLASS I
1. An initial TTE study is recommended in patients after pros-
thetic valve implantation for evaluation of valve hemodynamics
(248–251). (Level of Evidence: B)
Table 17. Stages of TR
Stage Deﬁnition Valve Anatomy Valve Hemodynamics* Hemodynamic Consequences Symptoms
A At risk of TR Primary
 Mild rheumatic change
 Mild prolapse
 Other (e.g., IE with vegetation,
early carcinoid deposition,
radiation)
 Intra-annular RV pacemaker
or ICD lead
 Postcardiac transplant
(biopsy related)
Functional
 Normal
 Early annular dilation
 No or trace TR  None  None or in relation to
other left heart or
pulmonary/pulmonary
vascular disease
B Progressive TR Primary
 Progressive leaﬂet
deterioration/destruction
 Moderate-to-severe prolapse,
limited chordal rupture
Functional
 Early annular dilation
 Moderate leaﬂet tethering
Mild TR
 Central jet area <5.0 cm2
 Vena contracta width not
deﬁned
 CW jet density and contour:
soft and parabolic
 Hepatic vein ﬂow: systolic
dominance
Moderate TR
 Central jet area 5–10 cm2
 Vena contracta width not
deﬁned but <0.70 cm
 CW jet density and contour:
dense, variable contour
 Hepatic vein ﬂow: systolic
blunting
Mild TR
 RV/RA/IVC size normal
Moderate TR
 No RV enlargement
 No or mild RA enlargement
 No or mild IVC enlargement
with normal respirophasic
variation
 Normal RA pressure
 None or in relation to
other left heart or
pulmonary/pulmonary
vascular disease
C Asymptomatic
severe TR
Primary
 Flail or grossly distorted
leaﬂets
Functional
 Severe annular dilation
(>40 mm or 21 mm/m2)
 Marked leaﬂet tethering
 Central jet area >10.0 cm2
 Vena contracta width >0.7 cm
 CW jet density and contour:
dense, triangular with early
peak
 Hepatic vein ﬂow: systolic
reversal
 RV/RA/IVC dilated with
decreased IVC respirophasic
variation
 Elevated RA pressure with
“c-V” wave
 Diastolic interventricular
septal ﬂattening may be present
 None, or in relation to
other left heart or
pulmonary/pulmonary
vascular disease
D Symptomatic
severe TR
Primary
 Flail or grossly distorted
leaﬂets
Functional
 Severe annular dilation
(>40 mm or >21 mm/m2)
 Marked leaﬂet tethering
 Central jet area >10.0 cm2
 Vena contracta width
>0.70 cm
 CW jet density and contour:
dense, triangular with early
peak
 Hepatic vein ﬂow: systolic
reversal
 RV/RA/IVC dilated with
decreased IVC respirophasic
variation
 Elevated RA pressure with
“c-V” wave
 Diastolic interventricular septal
ﬂattening
 Reduced RV systolic function
in late phase
 Fatigue, palpitations,
dyspnea, abdominal
bloating, anorexia,
edema
*Several valve hemodynamic criteria are provided for assessment of severity of TR, but not all criteria for each category will necessarily be present in every patient. Categorization of severity of TR as
mild, moderate, or severe also depends on image quality and integration of these parameters with clinical ﬁndings.
CW indicates continuous wave; ICD, implantable cardioverter-deﬁbrillator; IE, infective endocarditis; IVC, inferior vena cava; RA, right atrium; RV, right ventricle; and TR, tricuspid regurgitation.
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24612. Repeat TTE is recommended in patients with prosthetic heart
valves if there is a change in clinical symptoms or signs sug-
gesting valve dysfunction. (Level of Evidence: C)
3. TEE is recommended when clinical symptoms or signs suggest
prosthetic valve dysfunction. (Level of Evidence: C)
CLASS IIa
1. Annual TTE is reasonable in patients with a bioprosthetic valve
after the ﬁrst 10 years, even in the absence of a change in
clinical status. (Level of Evidence: C)
10.1.2. Intervention
See Table 21 for a summary of recommendations for
prosthetic valve choice.CLASS I
1. The choice of valve intervention, that is, repair or replacement, as
well as type of prosthetic heart valve, should be a shared decision-
making process that accounts for the patient’s values and pref-
erences, with full disclosure of the indications for and risks of
anticoagulant therapy and the potential need for and risk of
reoperation. (Level of Evidence: C)
2. A bioprosthesis is recommended in patients of any age for
whom anticoagulant therapy is contraindicated, cannot be
managed appropriately, or is not desired. (Level of Evidence: C)
CLASS IIa
1. A mechanical prosthesis is reasonable for AVR or MVR in pa-
tients less than 60 years of age who do not have a contraindi-
cation to anticoagulation (252–254). (Level of Evidence: B)
Figure 5. Indications for Surgery
*See Table 17 for deﬁnition of stages. TA dilation is deﬁned by >40 mm on TTE (>21 mm/m2) or >70 mm on direct intraoperative measurement.
LV indicates left ventricular; PHTN, pulmonary hypertension; RV, right ventricular; TA, tricuspid annular; TR, tricuspid regurgitation; TTE, transthoracic echocardiogram; TV,
tricuspid valve; and TVR, tricuspid valve replacement.
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24622. A bioprosthesis is reasonable in patients more than 70 years of
age (255–258). (Level of Evidence: B)
3. Either a bioprosthetic or mechanical valve is reasonable in pa-
tients between 60 and 70 years of age (259,260). (Level of
Evidence: B)
CLASS IIb
1. Replacement of the aortic valve by a pulmonary autograft (theRoss
procedure), when performed by an experienced surgeon, may be
considered in young patients when VKA anticoagulation is contra-
indicated or undesirable. (Level of Evidence: C)10.2. Antithrombotic Therapy for
Prosthetic Valves
CLASS I
1. Anticoagulation with a VKA and international normalized ratio
(INR) monitoring is recommended in patients with a mechanical
prosthetic valve (261–263). (Level of Evidence: A)Table 18. Stages of Severe TS
Stage Deﬁnition Valve Anatomy Valve Hemodynamics
C, D Severe TS  Thickened, distorted,
calciﬁed leaﬂets
 T 1/2 190 ms
 Valve area 1.0 cm
The transtricuspid diastolic gradient is highly variable and is affected by heart rate, forward ﬂow, and pha
mm Hg at heart rate 70 beats per minute.
bpm indicates beats per minute; IVC, inferior vena cava; RA, right atrium; T 1/2, pressure half-time; a2. Anticoagulation with a VKA to achieve an INR of 2.5 is rec-
ommended in patients with a mechanical AVR (bileaﬂet or
current-generation single tilting disc) and no risk factors for
thromboembolism (264–266). (Level of Evidence: B)
3. Anticoagulation with a VKA is indicated to achieve an INR of 3.0 in
patients with a mechanical AVR and additional risk factors for
thromboembolic events (AF, previous thromboembolism, LV dys-
function, or hypercoagulable conditions) or an older-generation me-
chanical AVR (such as ball-in-cage) (267). (Level of Evidence: B)
4. Anticoagulation with a VKA is indicated to achieve an INR of 3.0 in
patientswith amechanicalMVR (267,268). (Level of Evidence: B)
5. Aspirin 75 mg to 100 mg daily is recommended in addition to
anticoagulation with a VKA in patients with a mechanical valve
prosthesis (269,270). (Level of Evidence: A)
CLASS IIa
1. Aspirin 75 mg to 100 mg per day is reasonable in all patients
with a bioprosthetic aortic or mitral valve (271–274). (Level of
Evidence: B)Hemodynamic
Consequences Symptoms
2
 RA/IVC enlargement  None or variable and dependent on
severity of associated valve disease
and degree of obstruction
ses of the respiratory cycle. However, severe TS usually has mean pressure gradients >5 to 10
nd TS, tricuspid stenosis (9).
Table 19. Stages of Severe Pulmonic Regurgitation
Stage Deﬁnition Valve Anatomy Valve Hemodynamics Hemodynamic Consequences Symptoms
C, D Severe PR  Distorted or absent leaﬂets,
annular dilation
 Color jet ﬁlls RVOT
 CW jet density and contour: dense
laminar ﬂow with steep deceleration
slope; may terminate abruptly
 Paradoxical septal motion
(volume overload pattern)
 RV enlargement
 None or variable and dependent
on cause of PR and RV function
CW indicates continuous wave; PR, pulmonic regurgitation; RV, right ventricular; and RVOT, right ventricular outﬂow tract (247).
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24632. Anticoagulation with a VKA is reasonable for the ﬁrst 3 months
after bioprosthetic MVR or repair to achieve an INR of 2.5
(275). (Level of Evidence: C)
CLASS IIb
1. Anticoagulation, with a VKA, to achieve an INR of 2.5 may be
reasonable for the ﬁrst 3 months after bioprosthetic AVR (276).
(Level of Evidence: B)
2. Clopidogrel 75 mg daily may be reasonable for the ﬁrst
6 months after TAVR in addition to life-long aspirin 75 mg to
100 mg daily. (Level of Evidence: C)
CLASS III: Harm
1. Anticoagulant therapy with oral direct thrombin inhibitors or
anti-Xa agents should not be used in patients with mechanical
valve prostheses (277–279). (Level of Evidence: B)10.3. Bridging Therapy for Prosthetic Valves
CLASS I
1. Continuation of VKA anticoagulation with a therapeutic INR is
recommended in patients with mechanical heart valves un-
dergoing minor procedures (such as dental extractions or
cataract removal) where bleeding is easily controlled. (Level of
Evidence: C)
2. Temporary interruption of VKA anticoagulation, without bridging
agents while the INR is subtherapeutic, is recommended in
patients with a bileaﬂet mechanical AVR and no other risk
factors for thrombosis who are undergoing invasive or surgical
procedures. (Level of Evidence: C)
3. Bridging anticoagulation with either intravenous unfractio-
nated heparin (UFH) or subcutaneous low-molecular-weight
heparin (LMWH) is recommended during the time interval
when the INR is subtherapeutic preoperatively in patients who
are undergoing invasive or surgical procedures with a 1) me-
chanical AVR and any thromboembolic risk factor, 2) older-
generation mechanical AVR, or 3) mechanical MVR. (Level of
Evidence: C)
CLASS IIa
1. Administration of fresh frozen plasma or prothrombin complex
concentrate is reasonable in patients with mechanical valves
receiving VKA therapy who require emergency noncardiac sur-
gery or invasive procedures. (Level of Evidence: C)Table 20. Stages of Severe Pulmonic Stenosis
Stage Deﬁnition Valve Anatomy Valve Hemod
C, D Severe PS  Thickened, distorted, possibly
calciﬁed leaﬂets with systolic
doming and/or reduced excursion
 Other anatomic abnormalities may
be present, such as narrowed RVOT
 Vmax >4 m/
instantaneou
>64 mm Hg
PA indicates pulmonary artery; PS, pulmonic stenosis; RA, right atrium; RV, right ventricle; RVH
valve jet velocity (9).10.4. Excessive Anticoagulation and
Serious Bleeding With Prosthetic Valves
See Figure 6 for anticoagulation for prosthetic valves.
CLASS IIa
1. Administration of fresh frozen plasma or prothrombin complex
concentrate is reasonable in patients with mechanical valves
and uncontrollable bleeding who require reversal of anti-
coagulation (280,281). (Level of Evidence: B)10.5. Prosthetic Valve Thrombosis
See Figure 7 for evaluation and management of suspected
valve thrombosis.
10.5.1. Diagnosis and Follow-Up
CLASS I
1. TTE is indicated in patients with suspected prosthetic valve
thrombosis to assess hemodynamic severity and follow resolution
of valve dysfunction (282,283). (Level of Evidence: B)
2. TEE is indicated in patients with suspected prosthetic
valve thrombosis to assess thrombus size and valve motion
(283–285). (Level of Evidence: B)
CLASS IIa
1. Fluoroscopy or CT is reasonable in patients with suspected
valve thrombosis to assess valve motion. (Level of Evidence: C)
10.5.2. Medical Therapy
CLASS IIa
1. Fibrinolytic therapy is reasonable for patients with a throm-
bosed left-sided prosthetic heart valve, recent onset (<14 days)
of NYHA class I to II symptoms, and a small thrombus
(<0.8 cm2) (283,286). (Level of Evidence: B)
2. Fibrinolytic therapy is reasonable for thrombosed right-sided
prosthetic heart valves (287,288). (Level of Evidence: B)
10.5.3. Intervention
CLASS I
1. Emergency surgery is recommended for patients with a throm-
bosed left-sided prosthetic heart valve with NYHA class III to IV
symptoms (287,289,290). (Level of Evidence: B)ynamics Hemodynamic Consequences Symptoms
s; peak
s gradient
 RVH
 Possible RV, RA enlargement
 Poststenotic enlargement of
main PA
 None or variable and
dependent on severity
of obstruction
, right ventricular hypertrophy; RVOT, right ventricular outﬂow; and Vmax, maximal pulmonic
Table 21. Summary of Recommendations for Prosthetic Valve Choice
Recommendations COR LOE References
Choice of valve intervention and prosthetic valve type should be a shared decision process I C N/A
A bioprosthesis is recommended in patients of any age for whom anticoagulant therapy is
contraindicated, cannot be managed appropriately, or is not desired
I C N/A
A mechanical prosthesis is reasonable for AVR or MVR in patients <60 y of age who do not
have a contraindication to anticoagulation
IIa B (252–254)
A bioprosthesis is reasonable in patients >70 y of age IIa B (255–258)
Either a bioprosthetic or mechanical valve is reasonable in patients between 60 y and
70 y of age
IIa B (259,260)
Replacement of the aortic valve by a pulmonary autograft (the Ross procedure), when
performed by an experienced surgeon, may be considered in young patients when VKA
anticoagulation is contraindicated or undesirable
IIb C N/A
AVR indicates aortic valve replacement; COR, Class of Recommendation; LOE, Level of Evidence; MVR, mitral valve replacement; N/A, not applicable; and VKA, vitamin K antagonist.
Nishimura et al. JACC Vol. 63, No. 22, 2014
2014 AHA/ACC Valvular Heart Disease Guideline: Executive Summary June 10, 2014:2438–88
2464CLASS IIa
1. Emergency surgery is reasonable for patients with a thrombosed
left-sided prosthetic heart valve with a mobile or large thrombus
(>0.8 cm2) (283,285,290). (Level of Evidence: C)
10.6. Prosthetic Valve Stenosis
CLASS I
1. Repeat valve replacement is indicated for severe symptomatic
prosthetic valve stenosis. (Level of Evidence: C)Figure 6. Anticoagulation for Prosthetic Valves
Risk factors include AF, previous thromboembolism, LV dysfunction, hypercoagulable condi
AF indicates atrial ﬁbrillation; ASA, aspirin; AVR, aortic valve replacement; INR, internatio
replacement; PO, by mouth; QD, every day; SC, subcutaneous; TAVR, transcatheter aortic10.7. Prosthetic Valve Regurgitation
CLASS I
1. Surgery is recommended for operable patients with mechanical
heart valves with intractable hemolysis or HF due to severe
prosthetic or paraprosthetic regurgitation (291,292). (Level of
Evidence: B)CLASS IIa
1. Surgery is reasonable for operable patients with severe symptom-
aticorasymptomaticbioprosthetic regurgitation. (LevelofEvidenceC)tion, and older-generation mechanical AVR.
nal normalized ratio; LMWH, low-molecular-weight heparin; MVR, mitral valve
valve replacement; UFH, unfractionated heparin; and VKA, vitamin K antagonist.
Figure 7. Evaluation and Management of Suspected Prosthetic Valve Thrombosis
*See full-text guideline for dosage recommendations.
CT indicates computed tomography; IV, intravenous; NYHA, New York Heart Association; Rx, therapy; TEE, transesophageal echocardiography; and TTE, transthoracic
echocardiography.
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24652. Percutaneous repair of paravalvular regurgitation is reasonable
in patients with prosthetic heart valves and intractable hemo-
lysis or NYHA class III/IV HF who are at high risk for surgery and
have anatomic features suitable for catheter-based therapy
when performed in centers with expertise in the procedure
(293–295). (Level of Evidence B)
11. Infective Endocarditis: Recommendations
11.1. Diagnosis and Follow-Up
See Figure 8 for recommendations for imaging studies in
native valve endocarditis and prosthetic valve endocarditis.
CLASS I
1. At least 2 sets of blood cultures should be obtained in patients
at risk for IE (e.g., those with congenital or acquired VHD,
previous IE, prosthetic heart valves, certain congenital or heri-
table heart malformations, immunodeﬁciency states, injection
drug users) who have unexplained fever for more than 48 hours(296) (Level of Evidence: B) or patients with newly diagnosed
left-sided valve regurgitation. (Level of Evidence: C)
2. The Modiﬁed Duke Criteria should be used in evaluating a pa-
tient with suspected IE (Tables 24 and 25 in the full-text
guideline) (297–300). (Level of Evidence: B)
3. Patients with IE should be evaluated and managed with
consultation of a multispecialty Heart Valve Team including an
infectious disease specialist, cardiologist, and cardiac surgeon.
In surgically managed patients, this team should also include a
cardiac anesthesiologist (301). (Level of Evidence: B)
4. TTE is recommended in patients with suspected IE to identify
vegetations, characterize the hemodynamic severity of valvular
lesions, assess ventricular function and pulmonary pressures,
and detect complications (302–306). (Level of Evidence: B)
5. TEE is recommended in all patients with known or suspected IE
when TTE is nondiagnostic, when complications have developed
or are clinically suspected, or when intracardiac device leads
are present (307–315). (Level of Evidence: B)
6. TTE and/or TEE are recommended for re-evaluation of pa-
tients with IE who have a change in clinical signs or symptoms
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2466(e.g., new murmur, embolism, persistent fever, HF, abscess, or
atrioventricular heart block) and in patients at high risk of
complications (e.g., extensive infected tissue/large vegetation
on initial echocardiogram or staphylococcal, enterococcal,
fungal infections) (316,317). (Level of Evidence: B)
7. Intraoperative TEE is recommended for patients undergoing
valve surgery for IE (318,319). (Level of Evidence: B)
CLASS IIa
1. TEE is reasonable to diagnose possible IE in patients with
Staphylococcal aureus bacteremia without a known source
(320–322). (Level of Evidence: B)
2. TEE is reasonable to diagnose IE of a prosthetic valve in the
presence of persistent fever without bacteremia or a new
murmur (323,324). (Level of Evidence: B)
3. Cardiac CT is reasonable to evaluate morphology/anatomy in
the setting of suspected paravalvular infections when the
anatomy cannot be clearly delineated by echocardiography
(325–328). (Level of Evidence: B)
CLASS IIb
1. TEE might be considered to detect concomitant staphylococcal
IE in nosocomial Staphylococcal aureus bacteremia with a
known portal of entry from an extracardiac source (329–331).
(Level of Evidence: B)11.2. Medical Therapy
CLASS I
1. Appropriate antibiotic therapy should be initiated and continued
after blood cultures are obtained with guidance from antibiotic
sensitivity data and infectious disease consultants (296).
(Level of Evidence: B)Figure 8. Recommendations for Imaging Studies in NVE and PVE
*Repeat TEE and/or TTE recommended for reevaluation of patients with IE and a change in
CT indicates computed tomography; IE, infective endocarditis; NVE, native valve endocar
TEE, transesophageal echocardiography; and TTE, transthoracic echocardiography.CLASS IIa
1. It is reasonable to temporarily discontinue anticoagulation
in patients with IE who develop central nervous system symp-
toms compatible with embolism or stroke regardless of the other
indications for anticoagulation (332–337). (Level of Evidence: B)
CLASS IIb
1. Temporary discontinuation of VKA anticoagulation might be
considered in patients receiving VKA anticoagulation at the
time of IE diagnosis (333,338–341). (Level of Evidence: B)
CLASS III: Harm
1. Patients with known VHD should not receive antibiotics before
blood cultures are obtained for unexplained fever. (Level of
Evidence: C)11.3. Intervention
See Figure 9 for diagnosis and treatment of IE.
CLASS I
1. Decisions about timing of surgical intervention should be made
by a multispecialty Heart Valve Team of cardiology, cardiotho-
racic surgery, and infectious disease specialists (301). (Level of
Evidence: B)
2. Early surgery (during initial hospitalization before completion of
a full therapeutic course of antibiotics) is indicated in patients
with IE who present with valve dysfunction resulting in symp-
toms of HF (342–347). (Level of Evidence: B)
3. Early surgery (during initial hospitalization before completion of
a full therapeutic course of antibiotics) is indicated in patients
with left-sided IE caused by Staphylococcal aureus, fungal,
or other highly resistant organisms (347–354). (Level of
Evidence: B)clinical signs or symptoms and in patients at high risk of complications.
ditis; PVE, prosthetic valve endocarditis; S. aureus, Staphylococcus aureus;
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24674. Early surgery (during initial hospitalization before completion of
a full therapeutic course of antibiotics) is indicated in patients
with IE complicated by heart block, annular or aortic abscess,
or destructive penetrating lesions (347,355–359). (Level of
Evidence: B)
5. Early surgery (during initial hospitalization before completion of
a full therapeutic course of antibiotics) for IE is indicated
in patients with evidence of persistent infection as manifested
by persistent bacteremia or fevers lasting longer than 5 to
7 days after onset of appropriate antimicrobial therapy
(347,352,353,360–362). (Level of Evidence: B)
6. Surgery is recommended for patients with prosthetic valve
endocarditis and relapsing infection (deﬁned as recurrence
of bacteremia after a complete course of appropriate antibi-
otics and subsequently negative blood cultures) without
other identiﬁable source for portal of infection. (Level of
Evidence: C)
7. Complete removal of pacemaker or deﬁbrillator systems,
including all leads and the generator, is indicated as part of
the early management plan in patients with IE with docu-
mented infection of the device or leads (363–366). (Level of
Evidence: B)Figure 9. Diagnosis and Treatment of IE
*Early surgery deﬁned as during initial hospitalization before completion of a full therapeut
HF indicates heart failure; ICD, implantable cardioverter-deﬁbrillator; IE, infective endocar
S. aureus, Staphylococcus aureus; TEE, transesophageal echocardiography; TTE, transthoCLASS IIa
1. Complete removal of pacemaker or deﬁbrillator systems,
including all leads and the generator, is reasonable in patients
with valvular IE caused by Staphylococcal aureus or fungi, even
without evidence of device or lead infection (363–366). (Level
of Evidence: B)
2. Complete removal of pacemaker or deﬁbrillator systems,
including all leads and the generator, is reasonable in patients
undergoing valve surgery for valvular IE. (Level of Evidence: C)
3. Early surgery (during initial hospitalization before completion of
a full therapeutic course of antibiotics) is reasonable in patients
with IE who present with recurrent emboli and persistent veg-
etations despite appropriate antibiotic therapy (302,367,368).
(Level of Evidence: B)
CLASS IIb
1. Early surgery (during initial hospitalization before completion of
a full therapeutic course of antibiotics) may be considered in
patients with native valve endocarditis who exhibit mobile
vegetations greater than 10 mm in length (with or without
clinical evidence of embolic phenomenon) (302,367,368).
(Level of Evidence: B)ic course of antibiotics.
ditis; NVE, native valve endocarditis; PVE, prosthetic valve endocarditis; Rx, therapy;
racic echocardiography; and VKA, vitamin K antagonist.
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246812. Pregnancy and VHD: Recommendations
12.1. Native Valve Stenosis
CLASS I
1. All patients with suspected valve stenosis should undergo
a clinical evaluation and TTE before pregnancy. (Level of
Evidence: C)
2. All patients with severe valve stenosis (stages C and D) should
undergo prepregnancy counseling by a cardiologist with exper-
tise in managing patients with VHD during pregnancy. (Level of
Evidence: C)
3. All patients referred for a valve operation before pregnancy
should receive prepregnancy counseling by a cardiologist with
expertise in managing patients with VHD during pregnancy
about the risks and beneﬁts of all options for operative in-
terventions, including mechanical prosthesis, bioprosthesis,
and valve repair. (Level of Evidence: C)
4. Pregnant patients with severe valve stenosis (stages C and D)
should be monitored in a tertiary care center with a dedicated
Heart Valve Team of cardiologists, surgeons, anesthesiologists,
and obstetricians with expertise in the management of high-risk
cardiac patients during pregnancy. (Level of Evidence: C)
12.1.1. Diagnosis and Follow-Up
CLASS IIa
1. Exercise testing is reasonable in asymptomatic patients with
severe AS (aortic velocity ‡4.0 m per second or mean pressure
gradient ‡40 mm Hg, stage C) before pregnancy. (Level of
Evidence: C)
12.1.2. Medical Therapy
CLASS I
1. Anticoagulation should be given to pregnant patients with MS
and AF unless contraindicated. (Level of Evidence: C)
CLASS IIa
1. Use of beta blockers as required for rate control is reasonable
for pregnant patients with MS in the absence of contraindica-
tion if tolerated. (Level of Evidence: C)
CLASS IIb
1. Use of diuretics may be reasonable for pregnant patients with
MS and HF symptoms (stage D). (Level of Evidence: C)
CLASS III: Harm
1. ACE inhibitors and ARBs should not be given to pregnant patients
with valve stenosis (369–371). (Level of Evidence: B)
12.1.3. Intervention
CLASS I
1. Valve intervention is recommended before pregnancy for symp-
tomatic patients with severe AS (aortic velocity ‡4.0 m per
second or mean pressure gradient ‡40 mm Hg, stage D). (Level
of Evidence: C)
2. Valve intervention is recommended before pregnancy for
symptomatic patients with severe MS (mitral valve area £1.5
cm2, stage D). (Level of Evidence: C)
3. Percutaneous mitral balloon commissurotomy is recommended
before pregnancy for asymptomatic patients with severe MS(mitral valve area £1.5 cm2, stage C) who have valve
morphology favorable for percutaneous mitral balloon commis-
surotomy. (Level of Evidence: C)
CLASS IIa
1. Valve intervention is reasonable before pregnancy for asymp-
tomatic patients with severe AS (aortic velocity ‡4.0 m per
second or mean pressure gradient ‡40 mm Hg, stage C). (Level
of Evidence: C)
2. Percutaneous mitral balloon commissurotomy is reasonable for
pregnant patients with severe MS (mitral valve area £1.5 cm2,
stage D) with valve morphology favorable for percutaneous
mitral balloon commissurotomy who remain symptomatic with
NYHA class III to IV HF symptoms despite medical therapy
(372–376). (Level of Evidence: B)
3. Valve intervention is reasonable for pregnant patients with se-
vere MS (mitral valve area £1.5 cm2, stage D) and valve
morphology not favorable for percutaneous mitral balloon com-
missurotomy only if there are refractory NYHA class IV HF
symptoms. (Level of Evidence: C)
4. Valve intervention is reasonable for pregnant patients with se-
vere AS (mean pressure gradient ‡40 mm Hg, stage D) only if
there is hemodynamic deterioration or NYHA class III to IV HF
symptoms (377–383). (Level of Evidence: B)
CLASS III: Harm
1. Valve operation should not be performed in pregnant patients
with valve stenosis in the absence of severe HF symptoms.
(Level of Evidence: C)
12.2. Native Valve Regurgitation
12.2.1. Diagnosis and Follow-Up
CLASS I
1. All patients with suspected valve regurgitation should undergo
a clinical evaluation and TTE before pregnancy. (Level of
Evidence: C)
2. All patients with severe valve regurgitation (stages C and D)
should undergo prepregnancy counseling by a cardiologist with
expertise in managing patients with VHD during pregnancy.
(Level of Evidence: C)
3. All patients referred for a valve operation before pregnancy
should receive prepregnancy counseling by a cardiologist
with expertise in managing patients with VHD during preg-
nancy regarding the risks and beneﬁts of all options for
operative interventions, including mechanical prosthesis,
bioprosthesis, and valve repair. (Level of Evidence: C)
4. Pregnant patients with severe regurgitation (stages C and D)
should be monitored in a tertiary care center with a dedicated
Heart Valve Team of cardiologists, surgeons, anesthesiologists,
and obstetricians with expertise in managing high-risk cardiac
patients. (Level of Evidence: C)
CLASS IIa
1. Exercise testing is reasonable in asymptomatic patients with
severe valve regurgitation (stage C) before pregnancy. (Level of
Evidence: C)
12.2.2. Medical Therapy
CLASS III: Harm
1. ACE inhibitors and ARBs should not be given to pregnant pa-
tients with valve regurgitation (369–371). (Level of Evidence: B)
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246912.2.3. Intervention
CLASS I
1. Valve repair or replacement is recommended before pregnancy
for symptomatic women with severe valve regurgitation (stage
D). (Level of Evidence: C)
CLASS IIa
1. Valve operation for pregnant patients with severe valve regur-
gitation is reasonable only if there are refractory NYHA class IV
HF symptoms (stage D). (Level of Evidence: C)
CLASS IIb
1. Valve repair before pregnancy may be considered in the
asymptomatic patient with severe MR (stage C) and a valve
suitable for valve repair, but only after detailed discussion with
the patient about the risks and beneﬁts of the operation and its
outcome on future pregnancies. (Level of Evidence: C)
CLASS III: Harm
1. Valve operations should not be performed in pregnant patients
with valve regurgitation in the absence of severe intractable HF
symptoms. (Level of Evidence: C)12.3. Prosthetic Valves in Pregnancy
12.3.1. Diagnosis and Follow-Up
CLASS I
1. All patients with a prosthetic valve should undergo a clinical
evaluation and baseline TTE before pregnancy. (Level of
Evidence: C)
2. All patients with a prosthetic valve should undergo prepreg-
nancy counseling by a cardiologist with expertise in managing
patients with VHD during pregnancy. (Level of Evidence: C)
3. TTE should be performed in all pregnant patients with a pros-
thetic valve if not done before pregnancy. (Level of Evidence: C)
4. Repeat TTE should be performed in all pregnant patients with a
prosthetic valve who develop symptoms. (Level of Evidence: C)
5. TEE should be performed in all pregnant patients with a me-
chanical prosthetic valve who have prosthetic valve obstruction
or experience an embolic event. (Level of Evidence: C)
6. Pregnant patients with a mechanical prosthesis should be
monitored in a tertiary care center with a dedicated Heart Valve
Team of cardiologists, surgeons, anesthesiologists, and obste-
tricians with expertise in the management of high-risk cardiac
patients. (Level of Evidence: C)
12.3.2. Medical Therapy
See Figure 10 for anticoagulation of pregnant patients with
mechanical valves.
CLASS I
1. Therapeutic anticoagulation with frequent monitoring is rec-
ommended for all pregnant patients with a mechanical pros-
thesis (384,385). (Level of Evidence: B)
2. Warfarin is recommended in pregnant patients with a mechan-
ical prosthesis to achieve a therapeutic INR in the second and
third trimesters (386–391). (Level of Evidence: B)
3. Discontinuation of warfarin with initiation of intravenous UFH
(with an activated partial thromboplastin time [aPTT] >2 times
control) is recommended before planned vaginal delivery in
pregnant patients with a mechanical prosthesis. (Level of
Evidence: C)4. Low-dose aspirin (75 mg to 100 mg) once per day is recom-
mended for pregnant patients in the second and third trimesters
with either a mechanical prosthesis or bioprosthesis. (Level of
Evidence: C)
CLASS IIa
1. Continuation of warfarin during the ﬁrst trimester is reasonable
for pregnant patients with a mechanical prosthesis if the dose
of warfarin to achieve a therapeutic INR is 5 mg per day or less
after full discussion with the patient about risks and beneﬁts
(384,385,390–393). (Level of Evidence: B)
2. Dose-adjusted LMWH at least 2 times per day (with a target
anti-Xa level of 0.8 U/mL to 1.2 U/mL, 4 to 6 hours postdose)
during the ﬁrst trimester is reasonable for pregnant patients
with a mechanical prosthesis if the dose of warfarin is greater
than 5 mg per day to achieve a therapeutic INR
(386–389,394,395). (Level of Evidence: B)
3. Dose-adjusted continuous intravenous UFH (with an aPTT at
least 2 times control) during the ﬁrst trimester is reasonable
for pregnant patients with a mechanical prosthesis if the dose
of warfarin is greater than 5 mg per day to achieve a thera-
peutic INR (384,385,392). (Level of Evidence: B)
CLASS IIb
1. Dose-adjusted LMWH at least 2 times per day (with a target
anti-Xa level of 0.8 U/mL to 1.2 U/mL, 4 to 6 hours post-
dose) during the ﬁrst trimester may be reasonable for preg-
nant patients with a mechanical prosthesis if the dose of
warfarin is 5 mg per day or less to achieve a therapeutic INR
(386–389,394–396). (Level of Evidence: B)
2. Dose-adjusted continuous infusion of UFH (with aPTT at least 2
times control) during the ﬁrst trimester may be reasonable for
pregnant patients with a mechanical prosthesis if the dose of
warfarin is 5 mg per day or less to achieve a therapeutic INR
(384,385,392). (Level of Evidence: B)
CLASS III: Harm
1. LMWH should not be administered to pregnant patients with
mechanical prostheses unless anti-Xa levels are monitored 4 to
6 hours after administration (387,388,394,395,397). (Level of
Evidence: B)13. Surgical Considerations:
Recommendations
13.1. Evaluation of Coronary Anatomy
See Figure 11 for evaluation and management of CAD in
patients undergoing valve surgery.
CLASS I
1. Coronary angiography is indicated before valve intervention in
patients with symptoms of angina, objective evidence of
ischemia, decreased LV systolic function, history of CAD, or
coronary risk factors (including men age >40 years and post-
menopausal women). (Level of Evidence: C)
2. Coronary angiography should be performed as part of the eval-
uation of patients with chronic severe secondary MR. (Level of
Evidence: C)
CLASS IIa
1. Surgery without coronary angiography is reasonable for patients
having emergency valve surgery for acute valve regurgitation,
Figure 10. Anticoagulation of Pregnant Patients With Mechanical Valves
aPTT indicates activated partial thromboplastin time; ASA, aspirin; INR, international normalized ratio; LMWH, low-molecular-weight heparin; QD, once daily; and UFH,
unfractionated heparin.
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2470disease of the aortic sinuses or ascending aorta, or IE. (Level of
Evidence: C)
2. CT coronary angiography is reasonable to exclude the presence
of signiﬁcant obstructive CAD in selected patients with a low/
intermediate pretest probability of CAD. A positive coronary
CT angiogram (the presence of any epicardial CAD) can
be conﬁrmed with invasive coronary angiography (398–404).
(Level of Evidence: B)13.2. Concomitant Procedures
13.2.1. Intervention for CAD
CLASS IIa
1. CABG or percutaneous coronary intervention is reasonable
in patients undergoing valve repair or replacement with sig-
niﬁcant CAD (‡70% reduction in luminal diameter in majorcoronary arteries or ‡50% reduction in luminal diameter in the
left main coronary artery). (Level of Evidence: C)
13.2.2. Intervention for AF
CLASS IIa
1. A concomitant maze procedure is reasonable at the time of
mitral valve repair or replacement for treatment of chronic,
persistent AF. (Level of Evidence: C)
2. A full biatrial maze procedure, when technically feasible, is
reasonable at the time of mitral valve surgery, compared with a
lesser ablation procedure, in patients with chronic, persistent
AF (405,406). (Level of Evidence: B)
CLASS IIb
1. A concomitant maze procedure or pulmonary vein isolation may
be considered at the time of mitral valve repair or replacement
in patients with paroxysmal AF that is symptomatic or
Figure 11. Evaluation and Management of CAD in Patients Undergoing Valve Surgery
CABG indicates coronary artery bypass graft; CAD, coronary artery disease; CT, computed tomography; IE, infective endocarditis; LV, left ventricular; and PCI, percutaneous
coronary intervention.
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2471associated with a history of embolism on anticoagulation. (Level
of Evidence: C)
2. Concomitant maze procedure or pulmonary vein isolation may
be considered at the time of cardiac surgical procedures other
than mitral valve surgery in patients with paroxysmal or
persistent AF that is symptomatic or associated with a history
of emboli on anticoagulation. (Level of Evidence: C)
CLASS III: No Beneﬁt
1. Catheter ablation for AF should not be performed in patients
with severe MR when mitral repair or replacement is antici-
pated, with preference for the combined maze procedure plus
mitral valve repair (407). (Level of Evidence: B)
14. Noncardiac Surgery in Patients With VHD:
Recommendations
CLASS IIa
1. Moderate-risk elective noncardiac surgery with appropriate
intraoperative and postoperative hemodynamic monitoring is
reasonable to perform in patients with asymptomatic severe AS
(408–411). (Level of Evidence: B)
2. Moderate-risk elective noncardiac surgery with appropriate
intraoperative and postoperative hemodynamic monitoring isreasonable to perform in patients with asymptomatic severe
MR. (Level of Evidence: C)
3. Moderate-risk elective noncardiac surgery with appropriate
intraoperative and postoperative hemodynamic monitoring is
reasonable to perform in patients with asymptomatic severe AR
and a normal LVEF. (Level of Evidence: C)
CLASS IIb
1. Moderate-risk elective noncardiac surgery in patients with appro-
priate intraoperative and postoperative hemodynamic monitoring
may be reasonable to perform in asymptomatic patients with se-
vere MS if valve morphology is not favorable for percutaneous
balloon mitral commissurotomy. (Level of Evidence: C)
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